NL301301I2 - ciltacabtagene autoleucel - Google Patents

ciltacabtagene autoleucel

Info

Publication number: NL301301I2
Authority: NL; Netherlands
Prior art keywords: ciltacabtagene; autoleucel; ciltacabtagene autoleucel
Prior art date: 2015-08-11

Application number

NL301301C

Other languages

English (en)

Original Assignee

Legend Biotech Ireland Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-08-11

Filing date

2024-12-05

Publication date

2025-04-09

2024-12-05 Application filed by Legend Biotech Ireland Ltd filed Critical Legend Biotech Ireland Ltd

2025-04-09 Publication of NL301301I2 publication Critical patent/NL301301I2/nl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001116—Receptors for cytokines
- A61K39/001117—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR] or CD30
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
- A61K40/4211—CD19 or B4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4214—Receptors for cytokines
- A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4221—CD20
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4222—CD38 not IgG
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
- A61K2239/29—Multispecific CARs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Medicinal Chemistry (AREA)
Biophysics (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Engineering & Computer Science (AREA)
Cell Biology (AREA)
Biomedical Technology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
General Engineering & Computer Science (AREA)
Microbiology (AREA)
Hematology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Oncology (AREA)
Diabetes (AREA)
Mycology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

NL301301C 2015-08-11 2024-12-05 ciltacabtagene autoleucel NL301301I2 (nl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
CN201510490002		2015-08-11
CN201510733585.2A CN105384825B (zh)	2015-08-11	2015-11-02	一种基于单域抗体的双特异性嵌合抗原受体及其应用
PCT/CN2016/094408 WO2017025038A1 (en)	2015-08-11	2016-08-10	Chimeric antigen receptors based on single-domain antibodies and methods of use thereof
EP16834662.5A EP3334765A4 (en)	2015-08-11	2016-08-10	CHIMERIC ANTIGEN RECEPTORS BASED ON INDIVIDUAL DOMAIN ANTIBODIES AND METHOD FOR USE THEREOF

Publications (1)

Publication Number	Publication Date
NL301301I2 true NL301301I2 (nl)	2025-04-09

Family

ID=55417644

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL301301C NL301301I2 (nl)	2015-08-11	2024-12-05	ciltacabtagene autoleucel

Country Status (36)

Country	Link
US (6)	US10934363B2 (nl)
EP (7)	EP4063397B1 (nl)
JP (9)	JP6859347B2 (nl)
KR (7)	KR20180035918A (nl)
CN (9)	CN105384825B (nl)
AU (6)	AU2016305075B2 (nl)
BR (1)	BR112018002844A2 (nl)
CA (3)	CA2994579C (nl)
CL (4)	CL2018000378A1 (nl)
CO (2)	CO2018001405A2 (nl)
CR (4)	CR20210225A (nl)
DK (2)	DK4063397T3 (nl)
EA (2)	EA201890302A1 (nl)
ES (2)	ES2984851T3 (nl)
FI (3)	FI4063397T3 (nl)
FR (1)	FR24C1050I2 (nl)
HR (2)	HRP20241057T1 (nl)
HU (3)	HUE067869T2 (nl)
IL (3)	IL257297B (nl)
LT (3)	LT4063397T (nl)
MX (5)	MX2018001739A (nl)
MY (3)	MY188362A (nl)
NL (1)	NL301301I2 (nl)
NO (1)	NO2024054I1 (nl)
NZ (2)	NZ791176A (nl)
PH (2)	PH12018500295B1 (nl)
PL (2)	PL4063397T3 (nl)
PT (2)	PT4063397T (nl)
RS (2)	RS65866B1 (nl)
SA (2)	SA518390904B1 (nl)
SG (2)	SG10201913485QA (nl)
SI (2)	SI4063397T1 (nl)
SM (2)	SMT202400311T1 (nl)
UA (2)	UA125818C2 (nl)
WO (2)	WO2017025038A1 (nl)
ZA (2)	ZA201800703B (nl)

Families Citing this family (415)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9458450B2 (en)	2012-03-15	2016-10-04	Flodesign Sonics, Inc.	Acoustophoretic separation technology using multi-dimensional standing waves
US9950282B2 (en)	2012-03-15	2018-04-24	Flodesign Sonics, Inc.	Electronic configuration and control for acoustic standing wave generation
US10967298B2 (en)	2012-03-15	2021-04-06	Flodesign Sonics, Inc.	Driver and control for variable impedence load
US10704021B2 (en)	2012-03-15	2020-07-07	Flodesign Sonics, Inc.	Acoustic perfusion devices
EP3092049A1 (en)	2014-01-08	2016-11-16	Flodesign Sonics Inc.	Acoustophoresis device with dual acoustophoretic chamber
TWI746420B (zh)	2014-04-07	2021-11-21	美商密內瓦生物技術公司	抗ｎｍｅ抗體
CN104004095B (zh) *	2014-06-04	2016-11-23	博生吉医药科技(苏州)有限公司	一种cd7纳米抗体、其编码序列及应用
DK3240805T3 (da)	2014-12-15	2025-02-10	Univ California	Bispecifik or-gate kimærisk antigenreceptor, som reagerer på cd19 og cd20
US11377651B2 (en)	2016-10-19	2022-07-05	Flodesign Sonics, Inc.	Cell therapy processes utilizing acoustophoresis
US11420136B2 (en)	2016-10-19	2022-08-23	Flodesign Sonics, Inc.	Affinity cell extraction by acoustics
US11021699B2 (en)	2015-04-29	2021-06-01	FioDesign Sonics, Inc.	Separation using angled acoustic waves
US11708572B2 (en)	2015-04-29	2023-07-25	Flodesign Sonics, Inc.	Acoustic cell separation techniques and processes
US10434153B1 (en)	2015-05-20	2019-10-08	Kim Leslie O'Neill	Use of car and bite technology coupled with an scFv from an antibody against human thymidine kinase 1 to specifically target tumors
IL274151B (en)	2015-05-21	2022-07-01	Harpoon Therapeutics Inc	Trispecific binding proteins and methods of use
EP3313872A4 (en) *	2015-06-25	2019-03-20	iCell Gene Therapeutics LLC	CHIMERIC ANTIGEN RECEPTORS (CARS) COMPOSITIONS AND METHOD FOR USE THEREOF
US11474085B2 (en)	2015-07-28	2022-10-18	Flodesign Sonics, Inc.	Expanded bed affinity selection
US11459540B2 (en)	2015-07-28	2022-10-04	Flodesign Sonics, Inc.	Expanded bed affinity selection
CN105384825B (zh) *	2015-08-11	2018-06-01	南京传奇生物科技有限公司	一种基于单域抗体的双特异性嵌合抗原受体及其应用
JP7190901B2 (ja)	2016-01-12	2022-12-16	クレッシェンド、バイオロジックス、リミテッド	前立腺特異的膜抗原（ｐｓｍａ）と結合する分子
SG11201806261XA (en)	2016-02-17	2018-09-27	Seattle Genetics Inc	Bcma antibodies and use of same to treat cancer and immunological disorders
CN105647946B (zh) *	2016-03-18	2019-09-20	江苏普瑞康生物医药科技有限公司	一种基于FcγRⅢa的嵌合基因及其用途
CA3019149A1 (en) *	2016-04-01	2017-10-05	Kite Pharma, Inc.	Chimeric antigen and t cell receptors and methods of use
TWI761831B (zh)	2016-04-01	2022-04-21	美商凱特製藥公司	嵌合抗原受體（ｃａｒ）和ｔ細胞受體（ｔｃｒ）及彼等之用途
US11214789B2 (en)	2016-05-03	2022-01-04	Flodesign Sonics, Inc.	Concentration and washing of particles with acoustics
US11085035B2 (en)	2016-05-03	2021-08-10	Flodesign Sonics, Inc.	Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
GB201607968D0 (en)	2016-05-06	2016-06-22	Crescendo Biolog Ltd	Chimeric antigen receptor
CN119060177A (zh)	2016-05-20	2024-12-03	哈普恩治疗公司	单结构域血清白蛋白结合蛋白质
US11623958B2 (en)	2016-05-20	2023-04-11	Harpoon Therapeutics, Inc.	Single chain variable fragment CD3 binding proteins
JP7432363B2 (ja)	2016-06-21	2024-02-16	テネオバイオ，インコーポレイテッド	Ｃｄ３結合抗体
CA3029197A1 (en) *	2016-06-24	2017-12-28	Icell Gene Therapeutics Llc	Chimeric antigen receptors (cars), compositions and methods thereof
JP2019527678A (ja)	2016-06-28	2019-10-03	ユーエムセー・ユトレヒト・ホールディング・ベー・フェー	ＣＤ３８に特異的に結合する抗体によるＩｇＥ媒介疾患の治療
CN109715670A (zh) *	2016-07-15	2019-05-03	波赛达治疗公司	对muc1特异性的嵌合抗原受体(car)及其使用方法
EP3485017A4 (en) *	2016-07-18	2020-03-04	Helix Biopharma Corp.	IMMUNE CELLS CAR DIRECTED AGAINST CARCINO-EMBRYONARY ANTIGEN CELL ADHESION MOLECULE 6 FOR CANCER TREATMENT
CR20220408A (es) *	2016-09-14	2022-10-20	Teneobio Inc	ANTICUERPOS DE UNIÓN A CD3(Divisional del Expediente 2019-198)
CN108699163B (zh) *	2016-09-28	2021-11-19	阿思科力(苏州)生物科技有限公司	一种多基因重组嵌合抗原受体分子及其应用
WO2018068201A1 (en) *	2016-10-11	2018-04-19	Nanjing Legend Biotech Co., Ltd.	Single-domain antibodies and variants thereof against ctla-4
CN106755108A (zh) *	2016-12-05	2017-05-31	刘晓明	一种表达cd19和cd20抗体基因嵌合抗原受体的慢病毒载体及其制备方法
CN106755109A (zh) *	2016-12-05	2017-05-31	刘晓明	一种表达人cd19和cd20嵌合抗原受体基因的慢病毒载体
CN106701827A (zh) *	2016-12-05	2017-05-24	刘晓明	表达cd19和cd20抗体基因嵌合抗原受体t细胞的转化及扩增培养与保存方法
BR112019011450A2 (pt)	2016-12-09	2019-10-15	Onkimmune Limited	células naturais killer modificadas e uso das mesmas
CN106822184A (zh) *	2016-12-15	2017-06-13	梁爱斌	多靶点联合的car‑t细胞制剂与制备方法
BR112019012354A2 (pt)	2016-12-21	2019-11-26	Teneobio Inc	anticorpos apenas de cadeia pesada anti-bcma
CN108276493B (zh) *	2016-12-30	2023-11-14	南京传奇生物科技有限公司	一种嵌合抗原受体及其应用
CN106749677B (zh) *	2017-01-04	2020-06-12	上海交通大学医学院附属瑞金医院	一种靶向mll白血病的双特异性嵌合抗原受体基因及其应用
EP3565841A1 (en)	2017-01-06	2019-11-13	Crescendo Biologics Limited	Single domain antibodies to programmed cell death (pd-1)
WO2018144535A1 (en)	2017-01-31	2018-08-09	Novartis Ag	Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
CN108395482B (zh) *	2017-02-08	2021-02-05	西比曼生物科技（香港）有限公司	一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
BR112019017120A8 (pt)	2017-02-17	2023-05-02	Hutchinson Fred Cancer Res	Terapias de combinação para tratamento de cânceres e distúrbios autoimunes relacionados a bcma
WO2018160754A2 (en)	2017-02-28	2018-09-07	Harpoon Therapeutics, Inc.	Inducible monovalent antigen binding protein
EP3619235A1 (en)	2017-04-11	2020-03-11	Inhibrx, Inc.	Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
CN108728465A (zh) *	2017-04-14	2018-11-02	深圳新诺微环生物科技有限公司	一种表达靶细胞-效应细胞桥接器的微环dna载体及其制备方法和应用
KR102762834B1 (ko)	2017-04-26	2025-02-07	유레카 쎄라퓨틱스, 인코포레이티드	키메라 활성화 수용체 및 키메라 자극 수용체를 발현하는 세포 및 그의 용도
WO2018201051A1 (en)	2017-04-28	2018-11-01	Novartis Ag	Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
US20200055948A1 (en)	2017-04-28	2020-02-20	Novartis Ag	Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
IL310031A (en)	2017-05-01	2024-03-01	Juno Therapeutics Inc	A combination of cellular therapy and an immune modulatory compound
WO2018209324A2 (en)	2017-05-11	2018-11-15	The Broad Institute, Inc.	Methods and compositions of use of cd8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof
JP7090347B2 (ja)	2017-05-12	2022-06-24	ハープーンセラピューティクス，インク．	メソテリン結合タンパク質
US10415017B2 (en)	2017-05-17	2019-09-17	Thunder Biotech, Inc.	Transgenic macrophages, chimeric antigen receptors, and associated methods
EP3624834A1 (en) *	2017-05-17	2020-03-25	Thunder Biotech Inc.	Transgenic macrophages, chimeric antigen receptors, and associated methods
CN107299110B (zh) *	2017-05-27	2019-11-22	上海优卡迪生物医药科技有限公司	一种基于octs技术的胰腺癌、恶性间皮瘤car-t治疗载体及其构建方法和应用
CN107245500B (zh) *	2017-05-27	2019-05-17	上海优卡迪生物医药科技有限公司	一种基于octs技术的淋系白血病car-t治疗载体及其构建方法和应用
CN107337736B (zh) *	2017-06-06	2019-07-26	上海优卡迪生物医药科技有限公司	Octs-car双靶向嵌合抗原受体、编码基因、重组表达载体及其构建和应用
US11897953B2 (en)	2017-06-14	2024-02-13	The Broad Institute, Inc.	Compositions and methods targeting complement component 3 for inhibiting tumor growth
JP7240335B2 (ja) *	2017-06-20	2023-03-15	テネオワン，インコーポレイテッド	抗ｂｃｍａ重鎖のみ抗体
IL271194B2 (en) *	2017-06-20	2024-10-01	Teneobio Inc	Anti-bcma heavy chain-only antibodies
US12275787B2 (en)	2017-06-21	2025-04-15	Icell Gene Therapeutics Llc	Chimeric antigen receptors (CARs), compositions and methods thereof
WO2019000223A1 (en) *	2017-06-27	2019-01-03	Nanjing Legend Biotech Co., Ltd.	ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
SG11201913175TA (en) *	2017-06-30	2020-01-30	The United States Of America As Represented By The Secretary	Anti-b-cell maturation antigen chimeric antigen receptors with human domains
GB201711068D0 (en)	2017-07-10	2017-08-23	Crescendo Biologics Ltd	Therapeutic molecules binding PSMA
CN109232742B (zh) *	2017-07-11	2021-10-22	深圳市第二人民医院	一种嵌合抗原受体及其应用
WO2019014581A1 (en)	2017-07-14	2019-01-17	The Broad Institute, Inc.	METHODS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF A CYTOTOXIC LYMPHOCYTE
US11976121B2 (en) *	2017-07-20	2024-05-07	H. Lee Moffitt Cancer Center And Research Institute, Inc.	CD123-binding chimeric antigen receptors
WO2019014891A1 (zh) *	2017-07-20	2019-01-24	深圳普瑞金生物药业有限公司	一种用于治疗肿瘤的egfr单域抗体cart及其应用
JP7237926B2 (ja)	2017-07-31	2023-03-13	レンティジェン・テクノロジー・インコーポレイテッド	抗ｃｄ１９／ｃｄ２０免疫療法によりがんを処置するための組成物および方法
WO2019046818A1 (en) *	2017-09-01	2019-03-07	Dana-Farber Cancer Institute, Inc.	SPECIFIC IMMUNOGENIC PEPTIDES OF BCMA AND TACI ANTIGENS FOR THE TREATMENT OF CANCER
EP3681908A1 (en) *	2017-09-13	2020-07-22	Teneobio, Inc.	Heavy chain antibodies binding to ectoenzymes
BR112020006248A8 (pt) *	2017-09-29	2023-03-21	Mogam Inst Biomedical Res	Anticorpo anti-bcma com alta afinidade para bcma, polinucleotídeo, vetor de expressão, célula hospedeira, método para produção do dito anticorpo, composição farmacêutica compreendendo o mesmo e uso do anticorpo para prevenção ou tratamento de câncer
US12043870B2 (en)	2017-10-02	2024-07-23	The Broad Institute, Inc.	Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
IL315737A (en) *	2017-10-13	2024-11-01	Harpoon Therapeutics Inc	B-cell maturation antigen-binding proteins
EP3694529B1 (en)	2017-10-13	2024-06-26	Harpoon Therapeutics, Inc.	Trispecific proteins and methods of use
CN111629749A (zh)	2017-10-18	2020-09-04	诺华股份有限公司	用于选择性蛋白质降解的组合物和方法
WO2019090003A1 (en)	2017-11-01	2019-05-09	Juno Therapeutics, Inc.	Chimeric antigen receptors specific for b-cell maturation antigen (bcma)
KR20200099137A (ko)	2017-11-06	2020-08-21	주노 쎄러퓨티크스 인코퍼레이티드	세포 요법 및 감마 세크레타제 억제제의 조합
CA3082321A1 (en)	2017-11-13	2019-05-16	Crescendo Biologics Limited	Single domain antibodies that bind to cd137
WO2019094955A1 (en)	2017-11-13	2019-05-16	The Broad Institute, Inc.	Methods and compositions for targeting developmental and oncogenic programs in h3k27m gliomas
WO2019094983A1 (en)	2017-11-13	2019-05-16	The Broad Institute, Inc.	Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway
MX2020004948A (es)	2017-11-15	2020-11-11	Novartis Ag	Receptor de antígeno quimérico que selecciona como diana bcma, receptor de antígeno quimérico que selecciona como diana cd19 y terapias de combinación.
WO2019108900A1 (en)	2017-11-30	2019-06-06	Novartis Ag	Bcma-targeting chimeric antigen receptor, and uses thereof
CN111480345B (zh)	2017-12-14	2022-04-29	弗洛设计声能学公司	声泳系统及其操作方法、控制声换能器及声学系统的方法
US20190192678A1 (en) *	2017-12-18	2019-06-27	Novather, Inc.	System and method for the treatment of disease using a hyperspecific modified protein system
BR112020012555A2 (pt)	2017-12-20	2020-11-24	Poseida Therapeutics, Inc.	composições de vcar e métodos para uso
WO2019126724A1 (en) *	2017-12-22	2019-06-27	Bluebird Bio, Inc.	Multivalent chimeric antigen receptor
CN109970860A (zh) *	2017-12-27	2019-07-05	信达生物制药(苏州)有限公司	三链抗体、其制备方法及其用途
CN109971715A (zh) *	2017-12-28	2019-07-05	深圳华大生命科学研究院	一种扩增特异性car-t细胞的培养方法
WO2019127215A1 (en) *	2017-12-28	2019-07-04	Nanjing Legend Biotech Co., Ltd.	Multispecific chimeric receptors comprising an nkg2d domain and methods of use thereof
CN109988242A (zh) *	2018-01-02	2019-07-09	武汉波睿达生物科技有限公司	联合嵌合抗原受体、表达载体、慢病毒及t细胞
EP3737408A1 (en)	2018-01-08	2020-11-18	Novartis AG	Immune-enhancing rnas for combination with chimeric antigen receptor therapy
CN108285486A (zh) *	2018-01-15	2018-07-17	浙江阿思科力生物科技有限公司	以cd20为靶点的特异性抗体、car-nk细胞及其制备和应用
KR102115236B1 (ko) *	2018-01-29	2020-05-27	(주)에스엠티바이오	췌장 또는 담관계암 치료를 위한 키메라 항원 수용체
AU2019215031B2 (en)	2018-01-31	2025-10-09	Novartis Ag	Combination therapy using a chimeric antigen receptor
CN108341881B (zh) *	2018-01-31	2020-08-18	深圳市默赛尔生物医学科技发展有限公司	带安全开关的嵌合抗原受体及其表达基因、其修饰的nk细胞及应用
CN108314739B (zh) *	2018-02-05	2020-07-14	深圳市默赛尔生物医学科技发展有限公司	多信号嵌合抗原受体及其表达基因、其修饰的nk细胞及应用
CN110129369B (zh) *	2018-02-09	2023-10-13	上海交通大学医学院附属上海儿童医学中心	一种嵌合抗原受体基因工程载体、免疫细胞及其应用
US20200399383A1 (en)	2018-02-13	2020-12-24	Novartis Ag	Chimeric antigen receptor therapy in combination with il-15r and il15
GB201802573D0 (en)	2018-02-16	2018-04-04	Crescendo Biologics Ltd	Therapeutic molecules that bind to LAG3
WO2019166650A1 (en)	2018-03-02	2019-09-06	Cdr-Life Ag	Trispecific antigen binding proteins
CN108220247A (zh) *	2018-03-20	2018-06-29	杭州史迪姆生物科技有限公司	一种双car-t细胞及其制备方法和应用
EP3549597A1 (en) *	2018-04-06	2019-10-09	Heinrich-Heine-Universität Düsseldorf	Synthetic signalling constructs and its use
EP3773632A4 (en) *	2018-04-06	2022-05-18	The Regents of The University of California	Methods of treating egfrviii expressing glioblastomas
WO2019195596A1 (en)	2018-04-06	2019-10-10	The Regents Of The University Of California	Methods of treating glioblastomas
JP7724061B2 (ja)	2018-04-11	2025-08-15	インヒブルクスバイオサイエンシズインコーポレイテッド	制約されたｃｄ３結合を有する多重特異性ポリペプチド構築物ならびに関連する方法および使用
CN116514995A (zh)	2018-04-12	2023-08-01	上海赛比曼生物科技有限公司	靶向bcma的嵌合抗原受体及其制法和应用
US11957695B2 (en)	2018-04-26	2024-04-16	The Broad Institute, Inc.	Methods and compositions targeting glucocorticoid signaling for modulating immune responses
BR112020023330A2 (pt)	2018-05-14	2021-04-20	Harpoon Therapeutics, Inc.	porção de ligação para ativação condicional de moléculas de imunoglobulina
CA3100118A1 (en)	2018-05-16	2019-11-21	Janssen Biotech, Inc.	Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy
US20210371932A1 (en)	2018-06-01	2021-12-02	Massachusetts Institute Of Technology	Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
US12036240B2 (en)	2018-06-14	2024-07-16	The Broad Institute, Inc.	Compositions and methods targeting complement component 3 for inhibiting tumor growth
CN110606893B (zh) *	2018-06-15	2022-11-15	北昊干细胞与再生医学研究院有限公司	一种靶向cd19和cd20双抗原的嵌合性抗原受体t细胞治疗肿瘤的方法
WO2019242632A1 (en) *	2018-06-19	2019-12-26	1§1Nanjing Legend Biotech Co., Ltd.	Engineered cells and uses thereof
JP7439046B2 (ja) *	2018-07-20	2024-02-27	テネオツー・インコーポレイテッド	Ｃｄ１９に結合する重鎖抗体
TW202035451A (zh) *	2018-07-24	2020-10-01	美商英伊布里克斯公司	含有受限cd3結合域及受體結合區之多重特異性多肽構築體及其使用方法
MX2021001592A (es) *	2018-08-10	2021-09-21	Sangamo Therapeutics France	Nuevas construcciones de car que comprenden dominios de tnfr2.
GB201813178D0 (en) *	2018-08-13	2018-09-26	Autolus Ltd	Cell
AU2019323389B2 (en) *	2018-08-24	2024-03-21	Shenzhen Pregene Biopharma Co. Ltd.	Anti-BCMA single domain antibodies and application thereof
CN109134665B (zh) *	2018-08-24	2021-06-11	上海先博生物科技有限公司	一种基于单域抗体的bcma嵌合抗原受体及应用
US20210171909A1 (en)	2018-08-31	2021-06-10	Novartis Ag	Methods of making chimeric antigen receptor?expressing cells
SI3844267T1 (sl)	2018-08-31	2025-10-30	Novartis Ag	Postopki izdelave celic, ki izražajo receptorje himernega antigena
EP3850011A4 (en) *	2018-09-10	2022-10-19	Nanjing Legend Biotech Co., Ltd.	Single-domain antibodies against cd33 and constructs thereof
CN109293781A (zh) *	2018-09-12	2019-02-01	中国人民解放军总医院	嵌合抗原受体及其基因和重组表达载体、cd19-cd20双靶向性的t细胞及其应用
CN109081870B (zh) *	2018-09-21	2021-12-03	成都阿帕克生物科技有限公司	一种抗人促绒毛膜促性腺激素β亚单位的纳米抗体及核酸分子和应用
US12195544B2 (en)	2018-09-21	2025-01-14	Harpoon Therapeutics, Inc.	EGFR binding proteins and methods of use
CN109265550B (zh) *	2018-09-25	2020-09-15	华东师范大学	Bcma抗体、嵌合抗原受体和药物
WO2020069028A1 (en)	2018-09-25	2020-04-02	Harpoon Therapeutics, Inc.	Dll3 binding proteins and methods of use
JP2022501067A (ja) *	2018-09-26	2022-01-06	上海恒潤達生生物科技有限公司Hrain Biotechnology Co., Ltd.	Ｂｃｍａ及びｃｄ１９を標的とするキメラ抗原受容体、並びにその使用
US20210382068A1 (en)	2018-10-02	2021-12-09	Dana-Farber Cancer Institute, Inc.	Hla single allele lines
CN109503716B (zh) *	2018-10-08	2021-04-27	浙江生研生物科技有限公司	一种双特异性嵌合抗原受体分子及其在肿瘤治疗上的应用
TW202028245A (zh) *	2018-10-11	2020-08-01	美商英伊布里克斯公司	Dll3單域抗體及其治療性組合物
WO2020081730A2 (en)	2018-10-16	2020-04-23	Massachusetts Institute Of Technology	Methods and compositions for modulating microenvironment
JP2022505445A (ja) *	2018-10-26	2022-01-14	テネオバイオ，インコーポレイテッド	Ｃｄ３８に結合する重鎖抗体
WO2020092455A2 (en)	2018-10-29	2020-05-07	The Broad Institute, Inc.	Car t cell transcriptional atlas
CN113614108A (zh)	2018-11-01	2021-11-05	朱诺治疗学股份有限公司	G蛋白偶合受体c类5族成员d(gprc5d)特异性嵌合抗原受体
CN109504660B (zh) *	2018-11-02	2021-08-06	温州启星生物技术有限公司	一种第四代car-t细胞及其构建方法和应用
MX2021005366A (es)	2018-11-08	2021-09-10	Juno Therapeutics Inc	Metodos y combinaciones para el tratamiento y modulacion de celulas t.
CN110951689A (zh) *	2018-11-30	2020-04-03	北京美康基免生物科技有限公司	一种基于cd19和cd30的双重嵌合抗原受体基因修饰的免疫细胞及其应用
CN109468283A (zh) *	2018-11-30	2019-03-15	北京美康基免生物科技有限公司	一种基于cd19和bcma的双重嵌合抗原受体基因修饰的免疫细胞及其应用
CN120005921A (zh) *	2018-12-12	2025-05-16	凯德药业股份有限公司	嵌合抗原和t细胞受体及使用的方法
WO2020131586A2 (en)	2018-12-17	2020-06-25	The Broad Institute, Inc.	Methods for identifying neoantigens
CN109485732B (zh) *	2018-12-20	2021-09-24	四川大学华西医院	基因工程修饰的双靶点嵌合抗原受体及其用途
EP3902838A4 (en) *	2018-12-26	2022-12-21	Nanjing Legend Biotech Co., Ltd.	Cd30-binding moieties, chimeric antigen receptors, and uses thereof
CN109651511B (zh) *	2018-12-26	2020-06-09	广州百暨基因科技有限公司	一种靶向bcma的嵌合抗原受体及其应用
CN109652379B (zh) *	2018-12-29	2022-08-16	博生吉医药科技(苏州)有限公司	Cd7嵌合抗原受体修饰的nk-92mi细胞及其应用
CN109485734B (zh) *	2018-12-30	2020-05-12	广州百暨基因科技有限公司	一种靶向bcma和cd19的双特异性嵌合抗原受体及其应用
US11739156B2 (en)	2019-01-06	2023-08-29	The Broad Institute, Inc. Massachusetts Institute of Technology	Methods and compositions for overcoming immunosuppression
EP3908613A4 (en) *	2019-01-07	2022-10-19	Celluris Participações Ltda.	BISPECIFIC IN-TANDEM RECEPTOR CAR AND METHODS FOR MODULATION OF THE TUMOR MICROAREA
CN109678961A (zh) *	2019-01-15	2019-04-26	深圳市南科生物工程有限公司	一种基于bmca纳米抗体序列的嵌合抗原受体的构建方法及其应用
CN113330038A (zh) *	2019-01-22	2021-08-31	亘喜生物科技（上海）有限公司	Cd20组合靶向的工程化免疫细胞
AU2020212534A1 (en)	2019-01-22	2021-07-22	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	High affinity monoclonal antibodies targeting glypican-1 and methods of use
CN117264064A (zh) *	2019-02-04	2023-12-22	米纳瓦生物技术公司	抗nme抗体及治疗癌症或癌症转移的方法
CN109734814A (zh) *	2019-02-12	2019-05-10	南京卡提医学科技有限公司	具有免疫受体的工程化t细胞治疗癌症的用途
KR20210134339A (ko)	2019-02-25	2021-11-09	노파르티스 아게	바이러스 전달을 위한 메조다공성 실리카 입자 조성물
BR112021017537A2 (pt)	2019-03-05	2021-12-14	Nkarta Inc	Receptores de antígeno quimérico dirigidos a cd19 e usos dos mesmos em imunoterapia
US20220154282A1 (en)	2019-03-12	2022-05-19	The Broad Institute, Inc.	Detection means, compositions and methods for modulating synovial sarcoma cells
US20220142948A1 (en)	2019-03-18	2022-05-12	The Broad Institute, Inc.	Compositions and methods for modulating metabolic regulators of t cell pathogenicity
AU2020240132A1 (en)	2019-03-21	2021-09-16	Regeneron Pharmaceuticals, Inc.	Combination of IL-4/IL-13 pathway inhibitors and plasma cell ablation for treating allergy
EP3942025A1 (en)	2019-03-21	2022-01-26	Novartis AG	Car-t cell therapies with enhanced efficacy
EA202192736A1 (ru)	2019-04-05	2022-01-27	Тенеобио, Инк.	Антитела, содержащие только тяжелые цепи, которые связываются с псма
WO2020210678A1 (en)	2019-04-12	2020-10-15	Novartis Ag	Methods of making chimeric antigen receptor-expressing cells
AU2020261886A1 (en) *	2019-04-22	2021-11-18	Nanjing Legend Biotech Co., Ltd.	Engineered cells and uses thereof
CN109942709B (zh) *	2019-04-22	2019-12-27	广州百暨基因科技有限公司	一种抗bcma的单域抗体及其应用
EP3959320A1 (en)	2019-04-24	2022-03-02	Novartis AG	Compositions and methods for selective protein degradation
EP3733707A1 (en)	2019-04-30	2020-11-04	Celyad S.A.	Car t-cells targeting bcma and uses thereof
JP7711945B2 (ja)	2019-04-30	2025-07-23	センティバイオサイエンシズインコーポレイテッド	キメラ受容体及びその使用方法
MX2021013416A (es)	2019-05-04	2021-12-10	Inhibrx Inc	Polipeptidos de union al antigeno cd33 y sus usos.
US11162079B2 (en)	2019-05-10	2021-11-02	The Regents Of The University Of California	Blood type O Rh-hypo-immunogenic pluripotent cells
CN114245806A (zh)	2019-05-14	2022-03-25	哈普恩治疗公司	EpCAM结合蛋白及使用方法
US20220235340A1 (en)	2019-05-20	2022-07-28	The Broad Institute, Inc.	Novel crispr-cas systems and uses thereof
CA3139057A1 (en) *	2019-06-04	2020-12-10	Marcela V. Maus	Antibodies and chimeric antigen receptors that target taci
BR112021024956A2 (pt)	2019-06-14	2022-01-25	Teneobio Inc	Anticorpos multiespecíficos de cadeia pesada que se ligam a cd22 e cd3
AU2020307667A1 (en) *	2019-06-27	2022-01-20	Crispr Therapeutics Ag	Use of chimeric antigen receptor T cells and NK cell inhibitors for treating cancer
US20220282333A1 (en)	2019-08-13	2022-09-08	The General Hospital Corporation	Methods for predicting outcomes of checkpoint inhibition and treatment thereof
US12421557B2 (en)	2019-08-16	2025-09-23	The Broad Institute, Inc.	Methods for predicting outcomes and treating colorectal cancer using a cell atlas
CN110540997B (zh) *	2019-08-29	2024-02-13	浙江煦顼技术有限公司	靶向bcma嵌合抗原受体、核酸序列、载体及应用
UA128417C2 (uk) *	2019-08-30	2024-07-03	Янссен Байотек, Інк.	Car-t-конструкція і праймери комплексу дозрівання в-клітин
WO2021041922A1 (en)	2019-08-30	2021-03-04	The Broad Institute, Inc.	Crispr-associated mu transposase systems
WO2021043169A1 (zh) *	2019-09-02	2021-03-11	成都盛世君联生物技术有限公司	特异性结合b细胞成熟抗原的抗体及其用途
WO2021054789A1 (ko) *	2019-09-18	2021-03-25	주식회사 에스엘바이젠	신규 키메라 항원 수용체 암호화 유전자가 형질도입된 유전자 변형 nk 세포주 및 그의 용도
CN112739721B (zh) *	2019-09-26	2023-01-31	苏州克睿基因生物科技有限公司	一种单域抗体及包含抗体结构的嵌合抗原受体
US12297426B2 (en)	2019-10-01	2025-05-13	The Broad Institute, Inc.	DNA damage response signature guided rational design of CRISPR-based systems and therapies
US12394502B2 (en)	2019-10-02	2025-08-19	The General Hospital Corporation	Method for predicting HLA-binding peptides using protein structural features
US11981922B2 (en)	2019-10-03	2024-05-14	Dana-Farber Cancer Institute, Inc.	Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
US12195725B2 (en)	2019-10-03	2025-01-14	Dana-Farber Cancer Institute, Inc.	Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity
US11793787B2 (en)	2019-10-07	2023-10-24	The Broad Institute, Inc.	Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
JP2022553292A (ja) *	2019-10-21	2022-12-22	パーデュー・リサーチ・ファウンデーション	操作されたナチュラルキラー細胞、ならびに免疫療法およびオートファジー阻害技法においてそれを使用するための方法
AU2020370125A1 (en)	2019-10-22	2022-05-19	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	High affinity nanobodies targeting B7H3 (CD276) for treating multiple solid tumors
US11844800B2 (en)	2019-10-30	2023-12-19	Massachusetts Institute Of Technology	Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
KR20220100612A (ko)	2019-11-05	2022-07-15	얀센 바이오테크 인코포레이티드	다발성 골수종의 bcma-표적화 car-t 세포 요법
MX2022006391A (es)	2019-11-26	2022-06-24	Novartis Ag	Receptores de antigeno quimerico que se unen a bcma y cd19 y usos de los mismos.
WO2021105989A1 (en) *	2019-11-26	2021-06-03	Ramot At Tel-Aviv University Ltd.	Chimeric antigen receptor to carbohydrate antigens
CA3160765A1 (en) *	2019-12-10	2021-06-17	Abl Bio, Inc.	Anti-bcma/anti-4-1bb bispecific antibodies and uses thereof
IL293862A (en) *	2019-12-16	2022-08-01	Nanjing Legend Biotech Co Ltd	Single domain antibodies and chimeric antigen receptors targeting bcma and methods of use thereof
CN111171158B (zh) *	2020-01-17	2020-10-30	南京蓝盾生物科技有限公司	同时靶向bcma和cd38的嵌合抗原受体及其应用
CN111235113A (zh) *	2020-01-21	2020-06-05	南京北恒生物科技有限公司	包含嵌合抗原受体的免疫细胞及其用途
US12165747B2 (en)	2020-01-23	2024-12-10	The Broad Institute, Inc.	Molecular spatial mapping of metastatic tumor microenvironment
BR112022014667A2 (pt)	2020-01-29	2022-09-20	Inhibrx Inc	Anticorpos de domínio único de cd28 e construtos multivalentes e multiespecíficos dos mesmos
CN115397973A (zh) *	2020-01-30	2022-11-25	免疫生物公司	表达car的nk细胞消除bcma阳性恶性肿瘤
CN111196858B (zh) *	2020-02-05	2021-02-09	武汉科技大学	一种治疗血液肿瘤合并hiv感染的双特异性嵌合抗原受体、基因、构建方法及其应用
CN113166274B (zh) *	2020-02-13	2023-05-02	四川大学	一种嵌合抗原受体及应用
BR112022014722A2 (pt) *	2020-02-14	2022-10-11	Univ Leland Stanford Junior	Receptores de antígeno quiméricos com ativação de cd2
BR112022016633A2 (pt)	2020-02-27	2022-12-13	Novartis Ag	Métodos para produzir células que expressam receptor de antígeno quimérico
PH12022552283A1 (en)	2020-02-27	2024-01-22	Novartis Ag	Methods of making chimeric antigen receptor-expressing cells
US20210332448A1 (en) *	2020-03-09	2021-10-28	Janssen Pharmaceutica Nv	Compositions and methods for quantifying integration of recombinant vector nucleic acid
CN113402612A (zh)	2020-03-17	2021-09-17	西比曼生物科技（香港）有限公司	靶向cd19和cd20的联合嵌合抗原受体及其应用
CA3179800A1 (en)	2020-04-10	2021-10-14	Juno Therapeutics, Inc.	Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting b-cell maturation antigen
US20230165872A1 (en)	2020-04-28	2023-06-01	Juno Therapeutics, Inc.	Combination of bcma-directed t cell therapy and an immunomodulatory compound
US20230203161A1 (en)	2020-04-29	2023-06-29	Teneobio, Inc	Multispecific heavy chain antibodies with modified heavy chain constant regions
CN115777017A (zh) *	2020-05-06	2023-03-10	亘喜生物科技（上海）有限公司	用于t细胞工程改造的组合物及方法
CN111574629B (zh) *	2020-06-01	2021-07-20	宁夏医科大学	一种抗cd20的纳米抗体、编码基因、重组纳米抗体、重组载体、重组菌株和应用
CN111607565A (zh) *	2020-06-04	2020-09-01	河南大学	一种北平顶猴t细胞的体外扩增方法
CA3186600A1 (en) *	2020-06-08	2021-12-16	Janssen Biotech, Inc.	Cell-based assay for determining the in vitro tumor killing activity of chimeric antigen expressing immune cells
AU2021289677A1 (en)	2020-06-08	2023-01-19	Minerva Biotechnologies Corporation	Anti-NME antibody and method of treating cancer or cancer metastasis
CA3185455A1 (en)	2020-06-11	2021-12-16	Novartis Ag	Zbtb32 inhibitors and uses thereof
CN116829581A (zh)	2020-06-22	2023-09-29	莱蒂恩技术公司	用于用tslpr-cd19或tslpr-cd22免疫治疗来治疗癌症的组合物和方法
WO2021263227A2 (en) *	2020-06-26	2021-12-30	Minerva Biotechnologies Corporation	Anti-nme antibody and method of treating cancer or cancer metastasis
WO2022011531A1 (zh) *	2020-07-14	2022-01-20	浙江道尔生物科技有限公司	一种抗cld18a2的单域抗体
JP2023546765A (ja) *	2020-07-16	2023-11-08	レジェンドバイオテックユーエスエイインコーポレイテッド	Ｃｄ２０結合分子及びその使用
AU2021307644A1 (en) *	2020-07-16	2023-02-16	Legend Biotech Ireland Limited	CD22 binding molecules and uses thereof
WO2022012683A1 (en) *	2020-07-16	2022-01-20	Nanjing Legend Biotech Co., Ltd.	Cd19 binding molecules and uses thereof
IL299865A (en) *	2020-07-16	2023-03-01	Nanjing Legend Biotech Co Ltd	Multispecific chimeric antigen receptors and uses thereof
CN111848798B (zh) *	2020-07-27	2022-05-13	源道隆（苏州）医学科技有限公司	可结合bcma的纳米抗体及其应用
JP2023535485A (ja) *	2020-07-29	2023-08-17	ナショナルリサーチカウンシルオブカナダ	抗ｃｄ２２シングルドメイン抗体および治療用コンストラクト
CN111909271B (zh) *	2020-08-12	2021-03-23	深圳市茵冠生物科技有限公司	一种基于单域抗体的bcma嵌合抗原受体及其应用
WO2022035794A1 (en)	2020-08-13	2022-02-17	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Igg4 hinge-containing chimeric antigen receptors targeting glypican-1 (gpc1) for treating solid tumors
KR20230045095A (ko)	2020-08-20	2023-04-04	치아타이 티안큉 파마수티컬 그룹 주식회사	Bcma와 결합하는 단일 가변 도메인 및 항원 결합 분자
EP4202047A4 (en)	2020-08-20	2024-09-18	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	UNIQUE VARIABLE STRUCTURAL DOMAIN FOR BCMA BINDING AND ANTIGEN BINDING MOLECULE
IL300489A (en)	2020-08-21	2023-04-01	Novartis Ag	Compositions and methods for in vivo production of CAR expressing cells
CN112062864A (zh) *	2020-09-18	2020-12-11	樊克兴	靶向bcma肿瘤抗原受体修饰t细胞的制备方法和应用
CN111925451B (zh) *	2020-10-12	2021-01-29	佑仁细胞工程(浙江)有限公司	一种靶向bcma的嵌合抗原受体(car)及其应用
CN112251412B (zh) *	2020-10-12	2023-03-28	汤朝阳	一种靶向bcma的嵌合抗原受体t细胞及其应用
WO2022093745A1 (en)	2020-10-26	2022-05-05	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Single domain antibodies targeting sars coronavirus spike protein and uses thereof
CN112028996B (zh) *	2020-10-30	2021-01-22	南京北恒生物科技有限公司	靶向bcma的单域抗体及其用途
JP2023549780A (ja)	2020-11-04	2023-11-29	ジュノーセラピューティクスインコーポレイテッド	改変されたインバリアントｃｄ３免疫グロブリンスーパーファミリー鎖遺伝子座からキメラ受容体を発現する細胞ならびに関連するポリヌクレオチドおよび方法
WO2022116086A1 (en) *	2020-12-03	2022-06-09	Janssen Biotech, Inc.	Bcma-targeted car-t cell therapy for multiple myeloma
WO2022120160A1 (en)	2020-12-04	2022-06-09	Celgene Corporation	Uses of chimeric antigen receptor (car) t-cell therapies in combination with inhibitors of inflammation-related soluble factors
TW202237639A (zh)	2020-12-09	2022-10-01	日商武田藥品工業股份有限公司	鳥苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
TW202237638A (zh)	2020-12-09	2022-10-01	日商武田藥品工業股份有限公司	烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
MX2023006969A (es) *	2020-12-17	2023-08-25	Parasol Biotech Ltd	Moleculas de union a gucy2c y sus usos.
WO2022143611A1 (zh) *	2020-12-29	2022-07-07	宁波茂行生物医药科技有限公司	靶向bcma的单域抗体
EP4263590A1 (en)	2020-12-21	2023-10-25	Allogene Therapeutics, Inc.	Protease-activating cd45-gate car
CA3200509A1 (en)	2020-12-31	2022-07-07	Sonja SCHREPFER	Methods and compositions for modulating car-t activity
CN113087798B (zh) *	2020-12-31	2022-05-24	北京艺妙神州医药科技有限公司	一种抗bcma的抗体及其应用
TW202242121A (zh)	2021-01-11	2022-11-01	美商薩那生物科技公司	靶向cd8之病毒載體之用途
CN114149505B (zh) *	2021-01-12	2022-11-04	北京门罗生物科技有限公司	治疗b细胞相关疾病的免疫细胞、制备方法及其应用
US20240091356A1 (en) *	2021-01-27	2024-03-21	H. Lee Moffitt Cancer Center And Research Institute, Inc.	Bi-specific car t ccells for b cell malignancies
CN112778427B (zh) *	2021-01-29	2022-03-15	武汉思安医疗技术有限公司	双特异性cs1-bcma car-t细胞及其应用
EP4284918A1 (en)	2021-01-29	2023-12-06	Allogene Therapeutics, Inc.	Knockdown or knockout of one or more of tap2, nlrc5, beta2m, trac, rfx5, rfxap and rfxank to mitigate t cell recognition of allogeneic cell products
JP2024506200A (ja)	2021-02-15	2024-02-09	武田薬品工業株式会社	細胞治療用組成物及びｔｇｆ－ｂシグナル伝達を調節する方法
WO2022183160A1 (en) *	2021-02-25	2022-09-01	H. Lee Moffitt Cancer Center And Research Institute Inc.	Methods for treating cd83-expressing cancer
WO2022187406A1 (en)	2021-03-03	2022-09-09	Juno Therapeutics, Inc.	Combination of a t cell therapy and a dgk inhibitor
CN115109156B (zh) *	2021-03-22	2024-03-08	浙江纳米抗体技术中心有限公司	一种靶向bcma的纳米抗体及其应用
JP2024514107A (ja) *	2021-04-06	2024-03-28	テネオバイオ，インコーポレイテッド	抗ｃｄ１９抗体及びｃａｒ－ｔ構造体
EP4323387A4 (en) *	2021-04-13	2025-04-02	Wugen, Inc.	ENHANCED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES
TW202304963A (zh)	2021-04-15	2023-02-01	大陸商正大天晴藥業集團股份有限公司	標靶bcma的多特異性抗體
US20240207310A1 (en)	2021-04-16	2024-06-27	Celgene Corporation	Combination therapies with bcma-directed t cell therapy
WO2022221737A1 (en)	2021-04-16	2022-10-20	Juno Therapeutics, Inc.	T cell therapy in patients who have had prior stem cell transplant
EP4323403A1 (en) *	2021-04-16	2024-02-21	Teneobio, Inc.	Anti-cd20 antibodies and car-t structures
US20240384293A1 (en)	2021-04-27	2024-11-21	Novartis Ag	Viral vector production system
WO2022232612A1 (en)	2021-04-29	2022-11-03	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Lassa virus-specific nanobodies and methods of their use
WO2022228579A1 (en) *	2021-04-30	2022-11-03	Nanjing Legend Biotech Co., Ltd.	Chimeric antigen receptors targeting gpc3 and methods of use thereof
CN117916256A (zh)	2021-05-06	2024-04-19	朱诺治疗学有限公司	用于刺激和转导t细胞的方法
IL308345A (en)	2021-05-11	2024-01-01	Janssen Biotech Inc	Methods for Minimizing Neurotoxicity Associated with Chimeric Antigen Receptor (CAR) T Cell Therapy
TW202309522A (zh)	2021-05-11	2023-03-01	美商健生生物科技公司	用於監測復發性及／或難治性多發性骨髓瘤之治療的方法及組成物
BR112023024231A2 (pt)	2021-05-19	2024-01-30	Sana Biotechnology Inc	Células t primárias rhd negativas hipoimunogênicas
US20240245772A1 (en) *	2021-05-19	2024-07-25	Celledit Llc	Bi-specific chimeric antigen receptors and genetically engineered immune cells expressing such
US20240226164A1 (en)	2021-05-27	2024-07-11	Sana Biotechnology, Inc.	Hypoimmunogenic cells comprising engineered hla-e or hla-g
CA3216228A1 (en)	2021-06-09	2022-12-15	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Cross species single domain antibodies targeting pd-l1 for treating solid tumors
JP2024527559A (ja)	2021-07-01	2024-07-25	インダプタセラピューティクスインコーポレイテッド	操作されたナチュラルキラー（ｎｋ）細胞及び関連する方法
KR20240046319A (ko)	2021-07-14	2024-04-08	사나 바이오테크놀로지, 인크.	저면역원성 세포에서의 y 염색체-연결 항원의 변경된 발현
KR20240034234A (ko)	2021-07-14	2024-03-13	2세븐티 바이오, 인코포레이티드	항체로부터의 결합 도메인에 융합된 조작된 t 세포 수용체
TW202321457A (zh)	2021-08-04	2023-06-01	美商薩那生物科技公司	靶向ｃｄ４之病毒載體之用途
KR20240053673A (ko)	2021-08-11	2024-04-24	사나 바이오테크놀로지, 인크.	저면역원성 세포 내 유전자 발현을 변경하기 위한 유도성 시스템
CA3228773A1 (en) *	2021-08-12	2023-02-16	Gaurav KHARYA	Chimeric antigen receptors (car) for b cell malignancies
CN113651893B (zh) *	2021-08-12	2023-08-01	上海生物制品研究所有限责任公司	联合her2和meso双靶点car-t载体及其构建方法和在癌症中的应用
CN117858901A (zh)	2021-08-20	2024-04-09	诺华股份有限公司	制备表达嵌合抗原受体的细胞的方法
US11359012B1 (en)	2021-08-27	2022-06-14	Nanjing Kaedi Biotherapeutics Ltd.	Specific chimeric antigen receptor cells targeting human CLDN18A2, preparation method and application thereof
US11970548B2 (en) *	2021-08-27	2024-04-30	Innovative Cellular Therapeutics Holdings, Ltd.	Nanobody target GCC and uses in chimeric antigen receptor cell therapy
CN115894704B (zh) *	2021-09-24	2023-12-26	四川大学	一种特异性靶向肿瘤EpCAM抗原的抗体及应用
TW202325745A (zh) *	2021-09-29	2023-07-01	美商莫德斯醫療公司	抗原結合多肽、抗原結合多肽複合物及其使用方法
WO2023056555A1 (en) *	2021-10-07	2023-04-13	National Research Council Of Canada	Anti-bcma single domain antibodies and therapeutic constructs
WO2023069790A1 (en)	2021-10-22	2023-04-27	Sana Biotechnology, Inc.	Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods
WO2023076881A1 (en)	2021-10-26	2023-05-04	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Single domain antibodies targeting the s2 subunit of sars-cov-2 spike protein
CN114015674B (zh)	2021-11-02	2024-08-30	辉大(上海)生物科技有限公司	一种CRISPR-Cas12i系统
KR20240112994A (ko)	2021-11-03	2024-07-19	셀진 코포레이션	골수종을 치료하는 데 사용하기 위한 b-세포 성숙 항원에 특이적인 키메라 항원 수용체
IL312514A (en)	2021-11-03	2024-07-01	Janssen Biotech Inc	Corticosteroid reduction in treatment with anti-CD38 antibodies
WO2023077343A1 (en)	2021-11-04	2023-05-11	Janssen Biotech, Inc.	Bcma-targeted car-t cell therapy for multiple myeloma
JP2024540275A (ja)	2021-11-04	2024-10-31	ヤンセンバイオテック，インク．	Ｂｃｍａを標的とする、多発性骨髄腫のためのｃａｒ－ｔ細胞療法関連出願の相互参照
CN118556086A (zh)	2021-11-09	2024-08-27	美国政府(由卫生和人类服务部的部长所代表)	靶向磷脂酰肌醇蛋白聚糖-3（gpc3）的含有igg4铰链的嵌合抗原受体及其用途
CN115466331B (zh) *	2021-11-18	2023-05-30	合源生物科技(天津)有限公司	靶向bcma的嵌合抗原受体及其应用
KR20240136952A (ko) *	2021-12-07	2024-09-19	이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드	Bcma에 결합하는 항체 및 이의 용도
CN114195898B (zh) *	2021-12-13	2022-10-28	南京凯地医疗技术有限公司	人源化抗cd33的单域抗体及其构建体制备方法和应用
WO2023109257A1 (zh) *	2021-12-16	2023-06-22	浙江瑞加美生物科技有限公司	人源化的bcma抗体和bcma-car-t/bcma-car-dnt细胞
EP4448549A2 (en)	2021-12-17	2024-10-23	Sana Biotechnology, Inc.	Modified paramyxoviridae fusion glycoproteins
TW202342757A (zh)	2021-12-17	2023-11-01	美商薩那生物科技公司	經修飾副黏液病毒科附著醣蛋白
AU2022422147A1 (en)	2021-12-23	2024-07-04	Sana Biotechnology, Inc.	Chimeric antigen receptor (car) t cells for treating autoimmune disease and associated methods
CA3241112A1 (en) *	2021-12-29	2023-07-06	Arash Hatefi	Single-domain high affinity antibodies and methods of use thereof
WO2023133595A2 (en)	2022-01-10	2023-07-13	Sana Biotechnology, Inc.	Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
KR20240137075A (ko)	2022-01-28	2024-09-19	주노 쎄러퓨티크스 인코퍼레이티드	세포 조성물의 제조 방법
US20250152709A1 (en)	2022-02-01	2025-05-15	Sana Biotechnology, Inc.	Cd3-targeted lentiviral vectors and uses thereof
US20250144235A1 (en)	2022-02-02	2025-05-08	Sana Biotechnology, Inc.	Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
CN119156404A (zh)	2022-02-15	2024-12-17	美国政府(由卫生和人类服务部的部长所代表)	靶向gpc2的含有cd28铰链和跨膜结构的嵌合抗原受体及其用途
US20250333476A1 (en)	2022-02-17	2025-10-30	Sana Biotechnology, Inc.	Engineered cd47 proteins and uses thereof
WO2023164695A2 (en)	2022-02-28	2023-08-31	Janssen Biotech, Inc.	Bcma-targeted car-t cell therapy for multiple myeloma
WO2023193015A1 (en)	2022-04-01	2023-10-05	Sana Biotechnology, Inc.	Cytokine receptor agonist and viral vector combination therapies
AU2023248532A1 (en)	2022-04-08	2024-11-21	Regeneron Pharmaceuticals, Inc.	Multipartite receptor and signaling complexes
CN114685664B (zh) *	2022-04-12	2023-10-20	内蒙古农业大学	抗人b淋巴细胞表面抗原cd20的单域抗体及其应用
WO2023213969A1 (en)	2022-05-05	2023-11-09	Juno Therapeutics Gmbh	Viral-binding protein and related reagents, articles, and methods of use
CN119212724A (zh) *	2022-05-09	2024-12-27	上海先博生物科技有限公司	工程化免疫效应细胞及其与CBL-b抑制剂联用的应用
WO2023220641A2 (en)	2022-05-11	2023-11-16	Juno Therapeutics, Inc.	Methods and uses related to t cell therapy and production of same
US20250302954A1 (en)	2022-05-11	2025-10-02	Celgene Corporation	Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2023230581A1 (en)	2022-05-25	2023-11-30	Celgene Corporation	Methods of manufacturing t cell therapies
US20250345432A1 (en)	2022-05-25	2025-11-13	Celgene Corporation	Method for predicting response to a t cell therapy
AU2023276514A1 (en) *	2022-05-27	2024-12-05	Shenzhen Immunofoco Biotechnology Co., Ltd.	Chimeric antigen receptor containing cldn18.2 single domain antibody and application thereof
EP4536710A1 (en) *	2022-06-13	2025-04-16	The Regents of the University of California	Humanized antibodies to human integrin avb8
US12297285B2 (en) *	2022-06-24	2025-05-13	Orna Therapeutics, Inc.	Circular RNA encoding chimeric antigen receptors targeting BCMA
CN114805582B (zh) *	2022-06-29	2022-10-04	上海恒润达生生物科技股份有限公司	抗Trop2纳米抗体及其用途
CA3259982A1 (en)	2022-06-30	2024-01-04	Indapta Therapeutics, Inc.	COMBINATION OF MODIFIED NATURAL KILLER (NK) CELLS AND ANTIBODY THERAPY AND ASSOCIATED METHODS
WO2024026377A1 (en)	2022-07-27	2024-02-01	Sana Biotechnology, Inc.	Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
WO2024026445A1 (en)	2022-07-29	2024-02-01	Allogene Therapeutics Inc.	Engineered cells with reduced gene expression to mitigate immune cell recognition
WO2024026455A2 (en) *	2022-07-29	2024-02-01	Shoreline Biosciences, Inc.	Methods and compositions for generating chimeric antigen receptor-monocytes/macrophages
CN120051298A (zh)	2022-08-05	2025-05-27	朱诺治疗学股份有限公司	Gprc5d和bcma特异性嵌合抗原受体
EP4577575A1 (en) *	2022-08-25	2025-07-02	Nanjing Legend Biotech Co., Ltd.	Chimeric antigen receptors targeting interleukin 13 receptor subunit alpha 2 and methods of use thereof
WO2024050399A1 (en)	2022-09-01	2024-03-07	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Single domain antibodies targeting hpv e6/e7 oncogenic peptide/mhc complexes
CN116023495B (zh) *	2022-09-05	2023-10-03	上海百英生物科技股份有限公司	一种抗cd40纳米抗体及其制备方法与应用
WO2024054944A1 (en)	2022-09-08	2024-03-14	Juno Therapeutics, Inc.	Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing
WO2024064838A1 (en)	2022-09-21	2024-03-28	Sana Biotechnology, Inc.	Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
CN115925947B (zh) *	2022-09-27	2023-08-22	上海百英生物科技股份有限公司	一种亲和力成熟方法及抗人pd-l1单域抗体的亲和力成熟
EP4598949A1 (en)	2022-10-07	2025-08-13	The General Hospital Corporation	Methods and compositions for high-throughput discovery of peptide-mhc targeting binding proteins
EP4602174A1 (en)	2022-10-13	2025-08-20	Sana Biotechnology, Inc.	Viral particles targeting hematopoietic stem cells
EP4608983A1 (en)	2022-10-26	2025-09-03	Novartis AG	Lentiviral formulations
CN116120465B (zh) *	2022-11-01	2023-10-13	邦恩泰(山东)生物医药科技集团股份有限公司	一种靶向bcma和/或fcrh5的嵌合抗原受体及其应用
WO2024097905A1 (en)	2022-11-02	2024-05-10	Celgene Corporation	Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
AU2023373360A1 (en) *	2022-11-02	2025-06-12	Janssen Biotech, Inc.	Bcma-targeted car-t cell therapy of multiple myeloma
JP2025537156A (ja) *	2022-11-04	2025-11-14	ダナ－ファーバーキャンサーインスティテュート，インコーポレイテッド	Ｂｃｍａｖｈのみのｃａｒ
EP4615960A1 (en)	2022-11-09	2025-09-17	C3S2 GmbH	Methods for manufacturing engineered immune cells
WO2024119157A1 (en)	2022-12-02	2024-06-06	Sana Biotechnology, Inc.	Lipid particles with cofusogens and methods of producing and using the same
CN117069844B (zh) *	2022-12-06	2024-02-09	成都赛恩吉诺生物科技有限公司	包含特定等电点的抗人bcma纳米抗体的双特异性抗体及应用
EP4630043A1 (en)	2022-12-06	2025-10-15	Dynamic Cell Therapies, Inc.	Immune-activating complexes
EP4630446A1 (en)	2022-12-06	2025-10-15	Dynamic Cell Therapies, Inc.	Engineered switches for immune cell activity and methods of use thereof
WO2024124044A1 (en)	2022-12-07	2024-06-13	The Brigham And Women’S Hospital, Inc.	Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
WO2024124132A1 (en)	2022-12-09	2024-06-13	Juno Therapeutics, Inc.	Machine learning methods for predicting cell phenotype using holographic imaging
KR20240094169A (ko) *	2022-12-13	2024-06-25	진셀비티 주식회사	B-세포 성숙 항원을 표적화하는 신규한 키메라 항원 수용체 및 이의 용도
CN115947853B (zh) *	2022-12-26	2024-06-28	河北森朗生物科技有限公司	靶向bcma的纳米抗体、嵌合抗原受体及其应用
WO2024161021A1 (en)	2023-02-03	2024-08-08	Juno Therapeutics Gmbh	Methods for non-viral manufacturing of engineered immune cells
WO2024168192A1 (en)	2023-02-10	2024-08-15	Celgene Corporation	Assessment of bcma in biological samples
CN120098126A (zh) *	2023-02-22	2025-06-06	成都优赛诺生物科技有限公司	一种靶向cd22的单域抗体、嵌合抗原受体及其应用
KR20250153811A (ko)	2023-02-22	2025-10-27	아스트라제네카 아베	B 세포 성숙 항원(bcma)에 대한 키메라 항원 수용체를 사용하여 질병을 치료하는 조성물 및 방법
WO2024206209A1 (en) *	2023-03-27	2024-10-03	Modernatx, Inc.	Anti-cd38, anti-bcma, anti-gprc5d, and anti-fcrh5 antibodies and uses to treat various diseases such as cancer
EP4626447A1 (en)	2023-03-31	2025-10-08	AbelZeta Inc.	Bispecific chimeric antigen receptors targeting cd20 and bcma
CN116640229B (zh) *	2023-04-10	2024-01-30	中国人民解放军总医院第五医学中心	一种低pH靶向性CAR-T细胞的构建及应用
WO2024220598A2 (en)	2023-04-18	2024-10-24	Sana Biotechnology, Inc.	Lentiviral vectors with two or more genomes
WO2024220560A1 (en)	2023-04-18	2024-10-24	Sana Biotechnology, Inc.	Engineered protein g fusogens and related lipid particles and methods thereof
WO2024220574A1 (en)	2023-04-18	2024-10-24	Sana Biotechnology, Inc.	Universal protein g fusogens and adapter systems thereof and related lipid particles and uses
CA3205511A1 (en) *	2023-04-19	2025-03-17	Janssen Biotech, Inc.	Bcma-targeted car-t cell therapy for multiple myeloma
WO2024238346A1 (en)	2023-05-12	2024-11-21	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Single domain antibodies that specifically bind the s2 subunit of sars-cov-2 spike protein and compositions and uses thereof
AU2024274792A1 (en)	2023-05-23	2025-10-23	Sana Biotechnology, Inc.	Tandem fusogens and related lipid particles
WO2024240248A1 (zh) *	2023-05-24	2024-11-28	茂行制药(苏州)有限公司	用于靶向b7h3的同种异体嵌合抗原受体t细胞的给药的方法和组合物
CN117986387A (zh) *	2023-05-31	2024-05-07	四川大学华西医院	一种新型小型化car设计及制备方法和应用
AU2024279278A1 (en)	2023-05-31	2025-12-18	Capstan Therapeutics, Inc.	Lipid nanoparticle formulations and compositions
WO2025006799A1 (en)	2023-06-27	2025-01-02	Capstan Therapeutics, Inc.	Extracorporeal and ex vivo engineering of select cell populations from peripheral blood
CN116789859B (zh) *	2023-06-29	2024-02-23	徐州医科大学	一种用于评价bcma靶向car-t细胞药效的靶细胞及其应用
CN116949099B (zh) *	2023-07-12	2024-04-02	山东大学第二医院	一种靶向cd38和cs1抗原的并联嵌合抗原受体t细胞及其制备方法和应用
WO2025019228A1 (en)	2023-07-20	2025-01-23	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Fully human monoclonal antibodies and chimeric antigen receptors against cd276 for the treatment of solid tumors
WO2025029930A1 (en)	2023-07-31	2025-02-06	Legend Biotech Ireland Limited	Cells overexpressing cd31 and methods of use thereof
WO2025043172A1 (en)	2023-08-23	2025-02-27	Sana Biotechnology, Inc.	Modified cd47 proteins and their uses
GR1010884B (el) *	2023-08-30	2025-02-19	Janssen Biotech, Inc.,	Θεραπεια τ κυτταρων με χιμαιρικο υποδοχεα αντιγονου (car) με στοχευμενο αντιγονο ωριμανσης των β κυτταρων (bcma) για πολλαπλο μυελωμα
WO2025054202A1 (en)	2023-09-05	2025-03-13	Sana Biotechnology, Inc.	Method of screening a sample comprising a transgene with a unique barcode
WO2025059162A1 (en)	2023-09-11	2025-03-20	Dana-Farber Cancer Institute, Inc.	Car-engager containing il-2 variants to enhance the functionality of car t cells
WO2025059533A1 (en)	2023-09-13	2025-03-20	The Broad Institute, Inc.	Crispr enzymes and systems
CN117024594B (zh) *	2023-09-21	2025-02-28	武汉波睿达生物科技有限公司	一种抗cd20的纳米抗体及其应用
WO2025067472A1 (en) *	2023-09-27	2025-04-03	Nanjing Legend Biotech Co., Ltd.	Methods of culturing gamma delta t cells
WO2025076127A1 (en)	2023-10-05	2025-04-10	Capstan Therapeutics, Inc.	Constrained ionizable cationic lipids and lipid nanoparticles
US20250213690A1 (en)	2023-10-05	2025-07-03	Janssen Biotech, Inc.	Methods in lentiviral manufacturing for production of car-t cell drug products
WO2025076113A1 (en)	2023-10-05	2025-04-10	Capstan Therapeutics, Inc.	Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025096560A1 (en)	2023-10-30	2025-05-08	Allogene Therapeutics, Inc.	Engineered cells
WO2025096878A1 (en)	2023-11-02	2025-05-08	Capstan Therapeutics, Inc.	Rna for in vivo transfection with increased expression
WO2025097055A2 (en)	2023-11-02	2025-05-08	The Broad Institute, Inc.	Compositions and methods of use of t cells in immunotherapy
WO2025098446A1 (zh) *	2023-11-07	2025-05-15	赛斯尔擎生物技术（上海）有限公司	抗bcma单域抗体及其应用
GB202317065D0 (en)	2023-11-07	2023-12-20	Coding Bio Ltd	BCMA binding molecules
CN120025440A (zh) *	2023-11-21	2025-05-23	南京融捷康生物科技有限公司	一种抗Nkp46的单域抗体及其用途
WO2025117544A1 (en)	2023-11-29	2025-06-05	The Broad Institute, Inc.	Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof
US20250332281A2 (en)	2023-12-15	2025-10-30	Capstan Therapeutics, Inc.	Humanized anti-cd8 antibodies and uses thereof
WO2025130984A1 (en) *	2023-12-20	2025-06-26	Overland Therapeutics (Us) Inc.	Single domain antibodies for bcma
US20250230470A1 (en)	2024-01-12	2025-07-17	Sana Biotechnology, Inc.	Safety switches to control in vitro and in vivo proliferation of cell therapy products
KR102869233B1 (ko) *	2024-01-24	2025-10-15	주식회사 박셀바이오	Bcma 특이적 키메라 항원 수용체를 포함하는 신규한 골수 침윤 림프구 집단 및 이의 제조방법
WO2025160324A2 (en)	2024-01-26	2025-07-31	Regeneron Pharmaceuticals, Inc.	Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing
WO2025160340A2 (en)	2024-01-26	2025-07-31	Regeneron Pharmaceuticals, Inc.	Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
US20250269024A1 (en)	2024-02-05	2025-08-28	Legend Biotech Usa Inc.	Bcma-targeted car-t cell therapy for multiple myeloma
WO2025171383A2 (en)	2024-02-09	2025-08-14	Dispatch Biotherapeutics, Inc.	Engineered cancer antigens and related methods and uses
WO2025171388A1 (en)	2024-02-09	2025-08-14	Dispatch Biotherapeutics, Inc.	Engineered cancer antigens with modified domains and related methods and uses
WO2025179294A2 (en)	2024-02-22	2025-08-28	Capstan Therapeutics, Inc.	Immune engineering amplification
WO2025184529A1 (en)	2024-03-01	2025-09-04	Sana Biotechnology, Inc.	Viral particles with fusogen display and related compositions and methods
WO2025184567A1 (en)	2024-03-01	2025-09-04	Regeneron Pharmaceuticals, Inc.	Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
US20250339527A1 (en)	2024-03-12	2025-11-06	Legend Biotech Usa Inc.	Bcma-targeted car-t cell therapy for multiple myeloma
CN117866903B (zh) *	2024-03-12	2024-06-04	北京贝来药业有限公司	单域抗体修饰的干细胞及其在疾病治疗中用途
CN117866904B (zh) *	2024-03-12	2024-06-07	北京贝来药业有限公司	基于单域抗体基因修饰的干细胞对于多种的疾病的制药用途
WO2025217452A1 (en)	2024-04-11	2025-10-16	Capstan Therapeutics, Inc.	Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en)	2024-04-11	2025-10-16	Capstan Therapeutics, Inc.	Ionizable cationic lipids and lipid nanoparticles
WO2025221781A2 (en)	2024-04-15	2025-10-23	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Chimeric antigen receptors targeting fgfr4 and/or cd276 and use thereof for the treatment of cancer
WO2025231372A2 (en)	2024-05-03	2025-11-06	Janssen Biotech, Inc.	Methods for treating multiple myeloma with car-t cells and bispecific antibodies
WO2025231408A2 (en)	2024-05-03	2025-11-06	Janssen Biotech, Inc.	Methods for treating multiple myeloma with car-t cells and bispecific antibodies
WO2025232812A1 (en) *	2024-05-08	2025-11-13	Shanghai Vitalgen Biopharma Co., Ltd.	Biomolecule conjugated lipid nanoparticles
WO2025235598A1 (en)	2024-05-09	2025-11-13	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Chimeric antigen receptors targeting glypican-2 and/or cd276 and their use for treating solid tumors
WO2025240496A1 (en)	2024-05-14	2025-11-20	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Natural killer cells expressing a mesothelin-targeted chimeric antigen receptor and interleukin-15 for the treatment of solid tumors
WO2025255266A1 (en)	2024-06-05	2025-12-11	Dynamic Cell Therapies, Inc.	Engineered polypeptides for immune cell activation
WO2026006767A1 (en)	2024-06-28	2026-01-02	Dispatch Biotherapeutics, Inc.	Tethered il-9/il-9r and related engineered cells and methods
CN120173114B (zh) *	2025-03-24	2025-09-26	广州泽朗生物医药科技有限公司	Cart细胞及其在制备抗癌症药物中的应用

Family Cites Families (201)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US30985A (en)		1860-12-18		Thomas l
FR901228A (fr)	1943-01-16	1945-07-20	Deutsche Edelstahlwerke Ag	Système d'aimant à entrefer annulaire
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
USRE30985E (en)	1978-01-01	1982-06-29		Serum-free cell culture media
US4657760A (en)	1979-03-20	1987-04-14	Ortho Pharmaceutical Corporation	Methods and compositions using monoclonal antibody to human T cells
US4419446A (en)	1980-12-31	1983-12-06	The United States Of America As Represented By The Department Of Health And Human Services	Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4601978A (en)	1982-11-24	1986-07-22	The Regents Of The University Of California	Mammalian metallothionein promoter system
US4560655A (en)	1982-12-16	1985-12-24	Immunex Corporation	Serum-free cell culture medium and process for making same
US4657866A (en)	1982-12-21	1987-04-14	Sudhir Kumar	Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4767704A (en)	1983-10-07	1988-08-30	Columbia University In The City Of New York	Protein-free culture medium
US4965199A (en)	1984-04-20	1990-10-23	Genentech, Inc.	Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4737456A (en)	1985-05-09	1988-04-12	Syntex (U.S.A.) Inc.	Reducing interference in ligand-receptor binding assays
US5206344A (en)	1985-06-26	1993-04-27	Cetus Oncology Corporation	Interleukin-2 muteins and polymer conjugation thereof
GB8516415D0 (en)	1985-06-28	1985-07-31	Celltech Ltd	Culture of animal cells
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
US6548640B1 (en)	1986-03-27	2003-04-15	Btg International Limited	Altered antibodies
US4927762A (en)	1986-04-01	1990-05-22	Cell Enterprises, Inc.	Cell culture medium with antioxidant
IL85035A0 (en)	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en)	1987-03-18	1998-07-29	Scotgen Biopharmaceuticals, Inc.	Altered antibodies
US5770701A (en)	1987-10-30	1998-06-23	American Cyanamid Company	Process for preparing targeted forms of methyltrithio antitumor agents
US5606040A (en)	1987-10-30	1997-02-25	American Cyanamid Company	Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
WO1990003430A1 (en)	1988-09-23	1990-04-05	Cetus Corporation	Cell culture medium for enhanced cell growth, culture longevity and product expression
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
EP0368684B2 (en)	1988-11-11	2004-09-29	Medical Research Council	Cloning immunoglobulin variable domain sequences.
US6352694B1 (en)	1994-06-03	2002-03-05	Genetics Institute, Inc.	Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6534055B1 (en)	1988-11-23	2003-03-18	Genetics Institute, Inc.	Methods for selectively stimulating proliferation of T cells
US6905680B2 (en)	1988-11-23	2005-06-14	Genetics Institute, Inc.	Methods of treating HIV infected subjects
US5858358A (en)	1992-04-07	1999-01-12	The United States Of America As Represented By The Secretary Of The Navy	Methods for selectively stimulating proliferation of T cells
DE3920358A1 (de)	1989-06-22	1991-01-17	Behringwerke Ag	Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5225212A (en)	1989-10-20	1993-07-06	Liposome Technology, Inc.	Microreservoir liposome composition and method
US5208020A (en)	1989-10-25	1993-05-04	Immunogen Inc.	Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en)	1989-10-25	2006-02-07	Ravi J. Chari	Cytotoxic agents comprising maytansinoids and their therapeutic use
US6075181A (en)	1990-01-12	2000-06-13	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US6150584A (en)	1990-01-12	2000-11-21	Abgenix, Inc.	Human antibodies derived from immunized xenomice
ES2284161T3 (es)	1990-01-12	2007-11-01	Amgen Fremont Inc.	Generacion de anticuerpos xenogenicos.
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
DE69133476T2 (de)	1990-08-29	2006-01-05	GenPharm International, Inc., Palo Alto	Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5122469A (en)	1990-10-03	1992-06-16	Genentech, Inc.	Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5264365A (en)	1990-11-09	1993-11-23	Board Of Regents, The University Of Texas System	Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides
US5508192A (en)	1990-11-09	1996-04-16	Board Of Regents, The University Of Texas System	Bacterial host strains for producing proteolytically sensitive polypeptides
CA2405246A1 (en)	1990-12-03	1992-06-11	Genentech, Inc.	Enrichment method for variant proteins with alterred binding properties
US5571894A (en)	1991-02-05	1996-11-05	Ciba-Geigy Corporation	Recombinant antibodies specific for a growth factor receptor
DE122004000008I1 (de)	1991-06-14	2005-06-09	Genentech Inc	Humanisierter Heregulin Antikörper.
GB9114948D0 (en)	1991-07-11	1991-08-28	Pfizer Ltd	Process for preparing sertraline intermediates
EP0604580A1 (en)	1991-09-19	1994-07-06	Genentech, Inc.	EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
FI941572L (fi)	1991-10-07	1994-05-27	Oncologix Inc	Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en)	1991-11-04	1993-05-13	The Regents Of The University Of California	Compositions that mediate killing of hiv-infected cells
ATE297465T1 (de)	1991-11-25	2005-06-15	Enzon Inc	Verfahren zur herstellung von multivalenten antigenbindenden proteinen
ATE295420T1 (de)	1992-02-06	2005-05-15	Chiron Corp	Marker für krebs und biosynthetisches bindeprotein dafür
PT1589107E (pt)	1992-08-21	2010-03-29	Univ Bruxelles	Imunoglobulinas desprovidas de cadeias leves
PL174721B1 (pl)	1992-11-13	1998-09-30	Idec Pharma Corp	Przeciwciało monoklonalne anty-CD20
US5635483A (en)	1992-12-03	1997-06-03	Arizona Board Of Regents Acting On Behalf Of Arizona State University	Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en)	1993-01-26	1998-07-14	Arizona Board Of Regents	Elucidation and synthesis of selected pentapeptides
JPH08511420A (ja)	1993-06-16	1996-12-03	セルテック・セラピューテイクス・リミテッド	抗体
US7175843B2 (en)	1994-06-03	2007-02-13	Genetics Institute, Llc	Methods for selectively stimulating proliferation of T cells
US5773001A (en)	1994-06-03	1998-06-30	American Cyanamid Company	Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
WO2000032776A2 (en)	1998-12-01	2000-06-08	Genentech, Inc.	Secreted amd transmembrane polypeptides and nucleic acids encoding the same
US5639635A (en)	1994-11-03	1997-06-17	Genentech, Inc.	Process for bacterial production of polypeptides
US5840523A (en)	1995-03-01	1998-11-24	Genetech, Inc.	Methods and compositions for secretion of heterologous polypeptides
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
US5641870A (en)	1995-04-20	1997-06-24	Genentech, Inc.	Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en)	1995-04-14	1999-02-09	Genentech, Inc.	Altered polypeptides with increased half-life
EP0739981A1 (en)	1995-04-25	1996-10-30	Vrije Universiteit Brussel	Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
ATE390933T1 (de)	1995-04-27	2008-04-15	Amgen Fremont Inc	Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
EP0823941A4 (en)	1995-04-28	2001-09-19	Abgenix Inc	HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US6692964B1 (en)	1995-05-04	2004-02-17	The United States Of America As Represented By The Secretary Of The Navy	Methods for transfecting T cells
US7067318B2 (en)	1995-06-07	2006-06-27	The Regents Of The University Of Michigan	Methods for transfecting T cells
US5712374A (en)	1995-06-07	1998-01-27	American Cyanamid Company	Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en)	1995-06-07	1998-02-03	American Cyanamid Company	Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
GB9603256D0 (en)	1996-02-16	1996-04-17	Wellcome Found	Antibodies
US6027888A (en)	1996-04-05	2000-02-22	Board Of Regents, The University Of Texas System	Methods for producing soluble, biologically-active disulfide-bond containing eukaryotic proteins in bacterial cells
CA2258518C (en)	1996-06-27	2011-11-22	Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw	Recognition molecules interacting specifically with the active site or cleft of a target molecule
DK1500329T3 (da)	1996-12-03	2012-07-09	Amgen Fremont Inc	Humane antistoffer, der specifikt binder TNF-alfa
US6083715A (en)	1997-06-09	2000-07-04	Board Of Regents, The University Of Texas System	Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
AU757627B2 (en)	1997-06-24	2003-02-27	Genentech Inc.	Methods and compositions for galactosylated glycoproteins
JP2001521909A (ja)	1997-10-31	2001-11-13	ジェネンテク・インコーポレイテッド	糖タンパク質グリコフォームを含む方法及び組成物
US6610833B1 (en)	1997-11-24	2003-08-26	The Institute For Human Genetics And Biochemistry	Monoclonal human natural antibodies
WO1999029888A1 (en)	1997-12-05	1999-06-17	The Scripps Research Institute	Humanization of murine antibody
BR9907241A (pt)	1998-01-26	2000-10-17	Unilever Nv	Biblioteca de expressão, processo para preparar a mesma, uso de uma fonte não imunizada de sequências de ácido nucleico, e, processos para preparar fragmentos de anticorpos e, para preparar um anticorpo
US6194551B1 (en)	1998-04-02	2001-02-27	Genentech, Inc.	Polypeptide variants
ES2532910T3 (es)	1998-04-02	2015-04-01	Genentech, Inc.	Variantes de anticuerpos y fragmentos de los mismos
DK1071700T3 (da)	1998-04-20	2010-06-07	Glycart Biotechnology Ag	Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
US6737056B1 (en)	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
KR100887482B1 (ko)	1999-01-15	2009-03-10	제넨테크, 인크.	효과기 기능이 변화된 폴리펩티드 변이체
ATE276359T1 (de)	1999-01-19	2004-10-15	Unilever Nv	Verfahren zur herstellung von antikörperfragmenten
ES2569919T3 (es)	1999-04-09	2016-05-13	Kyowa Hakko Kirin Co., Ltd.	Procedimiento para controlar la actividad de una molécula inmunofuncional
JP2002541845A (ja)	1999-04-16	2002-12-10	セルテックセラピューティックスリミテッド	合成膜貫通成分
WO2001029246A1 (fr)	1999-10-19	2001-04-26	Kyowa Hakko Kogyo Co., Ltd.	Procede de production d'un polypeptide
AU784983B2 (en)	1999-12-15	2006-08-17	Genentech Inc.	Shotgun scanning, a combinatorial method for mapping functional protein epitopes
WO2001049698A1 (en)	1999-12-29	2001-07-12	Immunogen, Inc.	Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
US6867041B2 (en)	2000-02-24	2005-03-15	Xcyte Therapies, Inc.	Simultaneous stimulation and concentration of cells
KR20030032922A (ko)	2000-02-24	2003-04-26	싸이트 테라피스 인코포레이티드	세포의 동시 자극 및 농축
US7572631B2 (en)	2000-02-24	2009-08-11	Invitrogen Corporation	Activation and expansion of T cells
US6797514B2 (en)	2000-02-24	2004-09-28	Xcyte Therapies, Inc.	Simultaneous stimulation and concentration of cells
MXPA02010011A (es)	2000-04-11	2003-04-25	Genentech Inc	Anticuerpos multivalentes y usos para los mismos.
AU2001268855A1 (en)	2000-05-26	2001-12-03	National Research Council Of Canada	Single-domain antigen-binding antibody fragments derived from llama antibodies
PL218428B1 (pl)	2000-10-06	2014-12-31	Kyowa Hakko Kogyo Kk	Komórka, sposoby wytwarzania przeciwciał, leki zawierające przeciwciała, komórka CHO i przeciwciało klasy IgG
US7064191B2 (en)	2000-10-06	2006-06-20	Kyowa Hakko Kogyo Co., Ltd.	Process for purifying antibody
US6946292B2 (en)	2000-10-06	2005-09-20	Kyowa Hakko Kogyo Co., Ltd.	Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6596541B2 (en)	2000-10-31	2003-07-22	Regeneron Pharmaceuticals, Inc.	Methods of modifying eukaryotic cells
IL155977A0 (en)	2000-11-30	2003-12-23	Medarex Inc	Transgenic transchromosomal rodents for making human antibodies
GB0110029D0 (en)	2001-04-24	2001-06-13	Grosveld Frank	Transgenic animal
US20060073141A1 (en)	2001-06-28	2006-04-06	Domantis Limited	Compositions and methods for treating inflammatory disorders
EP2180044A1 (en)	2001-08-03	2010-04-28	GlycArt Biotechnology AG	Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity
CA2457636C (en)	2001-08-10	2012-01-03	Aberdeen University	Antigen binding domains
WO2003025020A1 (en)	2001-09-13	2003-03-27	Institute For Antibodies Co., Ltd.	Method of constructing camel antibody library
JP2005289809A (ja)	2001-10-24	2005-10-20	Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw)	突然変異重鎖抗体
PL213948B1 (pl)	2001-10-25	2013-05-31	Genentech Inc	Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
NZ532881A (en)	2001-12-20	2008-04-30	Human Genome Sciences Inc	Antibodies that immunospecifically bind to trail receptors
US20040093621A1 (en)	2001-12-25	2004-05-13	Kyowa Hakko Kogyo Co., Ltd	Antibody composition which specifically binds to CD20
US7745140B2 (en)	2002-01-03	2010-06-29	The Trustees Of The University Of Pennsylvania	Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
CA2481658A1 (en)	2002-04-09	2003-10-16	Kyowa Hakko Kogyo Co., Ltd.	Method of enhancing of binding activity of antibody composition to fcy receptor iiia
EP1502603A4 (en)	2002-04-09	2006-12-13	Kyowa Hakko Kogyo Kk	AN ANTIBODY COMPOSITION CONTAINING MEDICAMENT FOR PATIENTS WITH Fc gamma RIIIa POLYMORPHISM
ATE503829T1 (de)	2002-04-09	2011-04-15	Kyowa Hakko Kirin Co Ltd	Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
CA2481837A1 (en)	2002-04-09	2003-10-16	Kyowa Hakko Kogyo Co., Ltd.	Production process for antibody composition
US7691568B2 (en)	2002-04-09	2010-04-06	Kyowa Hakko Kirin Co., Ltd	Antibody composition-containing medicament
CN102911987B (zh)	2002-04-09	2015-09-30	协和发酵麒麟株式会社	基因组被修饰的细胞
NZ556507A (en)	2002-06-03	2010-03-26	Genentech Inc	Synthetic antibody phage libraries
US7361740B2 (en)	2002-10-15	2008-04-22	Pdl Biopharma, Inc.	Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
GB0228210D0 (en)	2002-12-03	2003-01-08	Babraham Inst	Single chain antibodies
UA89350C2 (uk)	2002-12-16	2010-01-25	Дженентек, Інк.	Гуманізоване антитіло, що зв'язує людський cd20
WO2004065416A2 (en)	2003-01-16	2004-08-05	Genentech, Inc.	Synthetic antibody phage libraries
AU2004279742A1 (en)	2003-10-08	2005-04-21	Kyowa Hakko Kirin Co., Ltd.	Fused protein composition
CA2542125A1 (en)	2003-10-09	2005-04-21	Kyowa Hakko Kogyo Co., Ltd.	Process for producing antibody composition by using rna inhibiting the function of .alpha.1,6-fucosyltransferase
ES2708095T3 (es)	2003-11-05	2019-04-08	Roche Glycart Ag	Anticuerpos de CD20 con afinidad de unión a receptor de Fc y función efectora incrementadas
NZ547633A (en)	2003-11-06	2010-08-27	Seattle Genetics Inc	Monomethylvaline compounds capable of conjugation to ligands
WO2005053742A1 (ja)	2003-12-04	2005-06-16	Kyowa Hakko Kogyo Co., Ltd.	抗体組成物を含有する医薬
WO2005097832A2 (en)	2004-03-31	2005-10-20	Genentech, Inc.	Humanized anti-tgf-beta antibodies
US7785903B2 (en)	2004-04-09	2010-08-31	Genentech, Inc.	Variable domain library and uses
NZ549872A (en)	2004-04-13	2009-09-25	Hoffmann La Roche	Anti-P-selectin antibodies
US7754482B2 (en)	2004-05-27	2010-07-13	The Trustees Of The University Of Pennsylvania	Artificial antigen presenting cells and uses therefor
EP2311874B1 (en)	2004-07-22	2017-05-31	Erasmus University Medical Center Rotterdam	Binding molecules
TWI380996B (zh)	2004-09-17	2013-01-01	Hoffmann La Roche	抗ｏｘ４０ｌ抗體
US7563443B2 (en)	2004-09-17	2009-07-21	Domantis Limited	Monovalent anti-CD40L antibody polypeptides and compositions thereof
KR101270829B1 (ko)	2004-09-23	2013-06-07	제넨테크, 인크.	시스테인 유전자조작 항체 및 접합체
EP2465870A1 (en)	2005-11-07	2012-06-20	Genentech, Inc.	Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
US20070237764A1 (en)	2005-12-02	2007-10-11	Genentech, Inc.	Binding polypeptides with restricted diversity sequences
EP1991580A2 (en)	2006-01-25	2008-11-19	Erasmus University Medical Center Rotterdam	Generation of heavy-chain only antibodies in transgenic animals
AU2007249408A1 (en)	2006-05-09	2007-11-22	Genentech, Inc.	Binding polypeptides with optimized scaffolds
US20100166734A1 (en)	2006-12-20	2010-07-01	Edward Dolk	Oral delivery of polypeptides
US20080226635A1 (en)	2006-12-22	2008-09-18	Hans Koll	Antibodies against insulin-like growth factor I receptor and uses thereof
CN100592373C (zh)	2007-05-25	2010-02-24	群康科技(深圳)有限公司	液晶显示面板驱动装置及其驱动方法
EP2170389B1 (en) *	2007-06-12	2014-10-29	AC Immune S.A.	Humanized antibodies to amyloid beta
US8975382B2 (en)	2007-11-27	2015-03-10	Ablynx N.V.	Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors
WO2009089004A1 (en)	2008-01-07	2009-07-16	Amgen Inc.	Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
CN101550416B (zh) *	2008-03-18	2012-01-25	陈志南	人源化单抗Hu-ScFv18的轻、重链可变区基因和其编码多肽及其应用
US20100122358A1 (en)	2008-06-06	2010-05-13	Crescendo Biologics Limited	H-Chain-only antibodies
CN110079550A (zh)	2009-12-10	2019-08-02	瑞泽恩制药公司	生产重链抗体的小鼠
RS59769B1 (sr) *	2010-06-09	2020-02-28	Genmab As	Antitela protiv humanog cd38
BR112013002578A2 (pt)	2010-08-03	2019-05-14	Abbvie Inc.	imunoglobinas de domínio variável duplo e usos das mesmas
US20130273055A1 (en)	2010-11-16	2013-10-17	Eric Borges	Agents and methods for treating diseases that correlate with bcma expression
DK2768942T3 (da)	2011-10-17	2020-01-27	Massachusetts Inst Technology	Intracellulær levering
TWI679212B (zh)	2011-11-15	2019-12-11	美商安進股份有限公司	針對ｂｃｍａ之e3以及ｃｄ３的結合分子
CA2861491C (en)	2012-02-13	2020-08-25	Seattle Children's Hospital D/B/A Seattle Children's Research Institute	Bispecific chimeric antigen receptors and therapeutic uses thereof
MX2014010185A (es) *	2012-02-22	2014-11-14	Univ Pennsylvania	Uso de dominio de señalizacion cd2 en receptores de antigeno quimericos de segunda generacion.
EP3689383B1 (en)	2012-04-11	2025-12-31	The United States Of America, As Represented By The Secretary, Department of Health and Human Services	Chimeric antigen receptors targeting a B lymphocyte maturation antigen
CN104583230A (zh) *	2012-07-13	2015-04-29	宾夕法尼亚大学董事会	通过共同引入双特异性抗体增强car t细胞的活性
EP2904106A4 (en) *	2012-10-01	2016-05-11	Univ Pennsylvania	COMPOSITIONS AND METHOD FOR TARGETING CURRIC ACIDS FOR THE TREATMENT OF CANCER
TW201425336A (zh)	2012-12-07	2014-07-01	Amgen Inc	Ｂｃｍａ抗原結合蛋白質
US9243058B2 (en) *	2012-12-07	2016-01-26	Amgen, Inc.	BCMA antigen binding proteins
DK2953972T3 (da) *	2013-02-05	2020-10-12	Engmab Sarl	Fremgangsmåde til udvælgelse af antistoffer mod bcma
CN104045713B (zh) *	2013-03-13	2019-02-12	江苏诺迈博生物医药科技有限公司	一种抗Blys的单克隆抗体及含有该抗体的药物组合物
ES2769574T3 (es)	2013-03-15	2020-06-26	Michael C Milone	Reconocimiento de células citotóxicas con receptores quiméricos para inmunoterapia adoptiva
UY35468A (es) *	2013-03-16	2014-10-31	Novartis Ag	Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
EP2981607B1 (en) *	2013-04-03	2020-08-19	Memorial Sloan Kettering Cancer Center	Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
CN103421115B (zh)	2013-09-02	2015-06-03	东南大学	一种cd38纳米抗体及应用
GB201317929D0 (en)	2013-10-10	2013-11-27	Ucl Business Plc	Chimeric antigen receptor
US10189908B2 (en)	2014-02-05	2019-01-29	The University Of Chicago	Chimeric antigen receptors recognizing cancer-specific TN glycopeptide variants
EP3811970A1 (en)	2014-03-15	2021-04-28	Novartis AG	Regulatable chimeric antigen receptor
WO2015142675A2 (en) *	2014-03-15	2015-09-24	Novartis Ag	Treatment of cancer using chimeric antigen receptor
CA3124228C (en)	2014-03-21	2024-05-14	Regeneron Pharmaceuticals, Inc.	Non-human animals that make single domain binding proteins
WO2015158671A1 (en)	2014-04-14	2015-10-22	Cellectis	Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
RS60106B1 (sr)	2014-04-25	2020-05-29	Bluebird Bio Inc	Mnd promoterni himerni antigenski receptori
PT3151672T (pt)	2014-06-06	2021-02-02	Bluebird Bio Inc	Composições de células t melhoradas
JP7054622B2 (ja)	2014-07-21	2022-04-14	ノバルティスアーゲー	ヒト化抗ｂｃｍａキメラ抗原受容体を使用した癌の処置
RU2747457C2 (ru)	2014-07-24	2021-05-05	Блубёрд Био, Инк.	Химерные антигенные рецепторы к bcma
HRP20191174T1 (hr) *	2014-08-04	2019-10-04	F. Hoffmann - La Roche Ag	Bispecifične molekule vezane na antigen koji aktivira t stanicu
EP3029067A1 (en)	2014-12-01	2016-06-08	Deutsches Krebsforschungszentrum	Use of blocking-reagents for reducing unspecific T cell-activation
WO2016090034A2 (en) *	2014-12-03	2016-06-09	Novartis Ag	Methods for b cell preconditioning in car therapy
HK1245801B (en)	2014-12-12	2020-05-15	2Seventy Bio, Inc.	Bcma chimeric antigen receptors
HK1258452A1 (zh)	2015-07-20	2019-11-15	Angiocrine Bioscience, Inc.	表达ets转录因子的工程化的内皮细胞
CN105384825B (zh)	2015-08-11	2018-06-01	南京传奇生物科技有限公司	一种基于单域抗体的双特异性嵌合抗原受体及其应用
CN105777911B (zh)	2016-04-12	2019-07-02	上海优卡迪生物医药科技有限公司	抗bcma嵌合抗原受体、编码基因、重组表达载体及其构建方法和应用
CN105837693A (zh)	2016-05-30	2016-08-10	李斯文	一种基于bcma的抗原嵌合受体及其制备方法和应用
CN108395481B (zh)	2017-02-08	2021-02-05	西比曼生物科技（香港）有限公司	一种靶向cd20的car的构建及其工程化t细胞的活性鉴定
KR20190141206A (ko)	2017-04-19	2019-12-23	알로젠 테라퓨틱스 인코포레이티드	개선된 t 세포 조성물 및 방법
WO2019000223A1 (en) *	2017-06-27	2019-01-03	Nanjing Legend Biotech Co., Ltd.	ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
CN109306014B (zh)	2017-07-27	2022-04-12	上海细胞治疗研究院	一种靶向间皮素的嵌合抗原受体修饰t细胞及其用途
CA3085606A1 (en)	2017-12-29	2019-07-04	Memorial Sloan-Kettering Cancer Center	Enhanced chimeric antigen receptors and uses thereof
US20210023170A1 (en)	2018-02-12	2021-01-28	University Of Florida Research Foundation, Incorporated	Fviii chimeric antigen receptor tregs for tolerance induction in hemophilia a
MX2022002325A (es)	2019-08-28	2022-06-02	Nanjing Legend Biotech Co Ltd	Linfocitos t que contienen nef y metodos para producirlos.
UA128417C2 (uk)	2019-08-30	2024-07-03	Янссен Байотек, Інк.	Car-t-конструкція і праймери комплексу дозрівання в-клітин
IL293862A (en)	2019-12-16	2022-08-01	Nanjing Legend Biotech Co Ltd	Single domain antibodies and chimeric antigen receptors targeting bcma and methods of use thereof
US20210332448A1 (en)	2020-03-09	2021-10-28	Janssen Pharmaceutica Nv	Compositions and methods for quantifying integration of recombinant vector nucleic acid
JP2023522400A (ja)	2020-04-24	2023-05-30	ヤンセンバイオテツク，インコーポレーテツド	手書きにおける変化を記述するための神経性毒性評価方法及びシステム
CA3186600A1 (en)	2020-06-08	2021-12-16	Janssen Biotech, Inc.	Cell-based assay for determining the in vitro tumor killing activity of chimeric antigen expressing immune cells

2015
- 2015-11-02 CN CN201510733585.2A patent/CN105384825B/zh active Active
2016
- 2016-08-10 IL IL257297A patent/IL257297B/en unknown
- 2016-08-10 LT LTEP22168161.2T patent/LT4063397T/lt unknown
- 2016-08-10 EA EA201890302A patent/EA201890302A1/ru unknown
- 2016-08-10 PT PT221681612T patent/PT4063397T/pt unknown
- 2016-08-10 KR KR1020187006996A patent/KR20180035918A/ko active Pending
- 2016-08-10 CR CR20210225A patent/CR20210225A/es unknown
- 2016-08-10 EP EP22168161.2A patent/EP4063397B1/en active Active
- 2016-08-10 WO PCT/CN2016/094408 patent/WO2017025038A1/en not_active Ceased
- 2016-08-10 SG SG10201913485QA patent/SG10201913485QA/en unknown
- 2016-08-10 ES ES22168161T patent/ES2984851T3/es active Active
- 2016-08-10 EP EP16834662.5A patent/EP3334765A4/en active Pending
- 2016-08-10 DK DK22168161.2T patent/DK4063397T3/da active
- 2016-08-10 US US15/751,609 patent/US10934363B2/en active Active
- 2016-08-10 PL PL22168161.2T patent/PL4063397T3/pl unknown
- 2016-08-10 HU HUE22168161A patent/HUE067869T2/hu unknown
- 2016-08-10 EP EP24174651.0A patent/EP4424376A3/en active Pending
- 2016-08-10 MX MX2018001739A patent/MX2018001739A/es unknown
- 2016-08-10 HR HRP20241057TT patent/HRP20241057T1/hr unknown
- 2016-08-10 MY MYPI2018000199A patent/MY188362A/en unknown
- 2016-08-10 IL IL294683A patent/IL294683A/en unknown
- 2016-08-10 RS RS20240831A patent/RS65866B1/sr unknown
- 2016-08-10 UA UAA201802367A patent/UA125818C2/uk unknown
- 2016-08-10 BR BR112018002844-4A patent/BR112018002844A2/pt active Search and Examination
- 2016-08-10 AU AU2016305075A patent/AU2016305075B2/en active Active
- 2016-08-10 CA CA2994579A patent/CA2994579C/en active Active
- 2016-08-10 SM SM20240311T patent/SMT202400311T1/it unknown
- 2016-08-10 KR KR1020247039135A patent/KR20240173368A/ko active Pending
- 2016-08-10 JP JP2018526984A patent/JP6859347B2/ja active Active
- 2016-08-10 PH PH1/2018/500295A patent/PH12018500295B1/en unknown
- 2016-08-10 CN CN201680047777.0A patent/CN109311999A/zh active Pending
- 2016-08-10 FI FIEP22168161.2T patent/FI4063397T3/fi active
- 2016-08-10 CR CR20180153A patent/CR20180153A/es unknown
- 2016-08-10 SI SI201631840T patent/SI4063397T1/sl unknown
2017
- 2017-08-10 CN CN202110529749.5A patent/CN113185616B/zh active Active
- 2017-08-10 PT PT211666623T patent/PT3896091T/pt unknown
- 2017-08-10 US US16/303,587 patent/US11535677B2/en active Active
- 2017-08-10 EP EP21166662.3A patent/EP3896091B1/en active Active
- 2017-08-10 SG SG11201900635QA patent/SG11201900635QA/en unknown
- 2017-08-10 CN CN202110530320.8A patent/CN113234173B/zh active Active
- 2017-08-10 CA CA3189388A patent/CA3189388A1/en active Pending
- 2017-08-10 NZ NZ791176A patent/NZ791176A/en unknown
- 2017-08-10 MY MYPI2019000175A patent/MY192392A/en unknown
- 2017-08-10 RS RS20231139A patent/RS64925B1/sr unknown
- 2017-08-10 ES ES21166662T patent/ES2966992T3/es active Active
- 2017-08-10 CN CN202110529747.6A patent/CN113185615A/zh active Pending
- 2017-08-10 EP EP17838777.5A patent/EP3475307A4/en not_active Withdrawn
- 2017-08-10 EA EA201990208A patent/EA201990208A1/ru unknown
- 2017-08-10 EP EP23199692.7A patent/EP4282878A3/en active Pending
- 2017-08-10 CN CN201780031233.XA patent/CN109153731B/zh active Active
- 2017-08-10 SI SI201731453T patent/SI3896091T1/sl unknown
- 2017-08-10 CN CN202410221549.7A patent/CN118085090A/zh active Pending
- 2017-08-10 CR CR20210042A patent/CR20210042A/es unknown
- 2017-08-10 KR KR1020257022322A patent/KR20250107971A/ko active Pending
- 2017-08-10 MY MYPI2021007296A patent/MY199874A/en unknown
- 2017-08-10 JP JP2019506627A patent/JP6851461B2/ja active Active
- 2017-08-10 KR KR1020247002596A patent/KR20240017408A/ko not_active Ceased
- 2017-08-10 HR HRP20231542TT patent/HRP20231542T1/hr unknown
- 2017-08-10 SM SM20230425T patent/SMT202300425T1/it unknown
- 2017-08-10 CN CN202410006229.XA patent/CN117756941A/zh active Pending
- 2017-08-10 CR CR20190050A patent/CR20190050A/es unknown
- 2017-08-10 LT LTEP21166662.3T patent/LT3896091T/lt unknown
- 2017-08-10 UA UAA201901062A patent/UA126441C2/uk unknown
- 2017-08-10 KR KR1020247002595A patent/KR20240014108A/ko not_active Ceased
- 2017-08-10 KR KR1020197001835A patent/KR102512934B1/ko active Active
- 2017-08-10 AU AU2017311089A patent/AU2017311089B2/en active Active
- 2017-08-10 DK DK21166662.3T patent/DK3896091T5/da active
- 2017-08-10 KR KR1020237009392A patent/KR20230052294A/ko not_active Ceased
- 2017-08-10 MX MX2019001294A patent/MX420844B/es unknown
- 2017-08-10 CN CN202110530335.4A patent/CN113234174B/zh active Active
- 2017-08-10 FI FIEP21166662.3T patent/FI3896091T3/fi active
- 2017-08-10 HU HUE21166662A patent/HUE064534T2/hu unknown
- 2017-08-10 WO PCT/CN2017/096938 patent/WO2018028647A1/en not_active Ceased
- 2017-08-10 PL PL21166662.3T patent/PL3896091T3/pl unknown
- 2017-08-10 EP EP23199446.8A patent/EP4282877A3/en active Pending
- 2017-08-10 NZ NZ750366A patent/NZ750366A/en unknown
- 2017-08-10 CA CA3019453A patent/CA3019453C/en active Active
2018
- 2018-02-02 ZA ZA2018/00703A patent/ZA201800703B/en unknown
- 2018-02-09 CL CL2018000378A patent/CL2018000378A1/es unknown
- 2018-02-09 MX MX2022015823A patent/MX2022015823A/es unknown
- 2018-02-11 SA SA518390904A patent/SA518390904B1/ar unknown
- 2018-02-13 CO CONC2018/0001405A patent/CO2018001405A2/es unknown
- 2018-11-21 ZA ZA2018/07836A patent/ZA201807836B/en unknown
2019
- 2019-01-28 PH PH12019500193A patent/PH12019500193A1/en unknown
- 2019-01-30 CO CONC2019/0000946A patent/CO2019000946A2/es unknown
- 2019-01-30 MX MX2024010240A patent/MX2024010240A/es unknown
- 2019-01-30 MX MX2024010239A patent/MX2024010239A/es unknown
- 2019-02-03 IL IL264607A patent/IL264607A/en unknown
- 2019-02-07 CL CL2019000326A patent/CL2019000326A1/es unknown
- 2019-02-10 SA SA519401072A patent/SA519401072B1/ar unknown
2020
- 2020-01-08 AU AU2020200151A patent/AU2020200151C1/en active Active
2021
- 2021-01-22 AU AU2021200453A patent/AU2021200453C1/en active Active
- 2021-02-01 US US17/164,125 patent/US20210261675A1/en active Pending
- 2021-02-04 US US17/168,100 patent/US11186647B2/en active Active
- 2021-03-09 JP JP2021037374A patent/JP7696731B2/ja active Active
- 2021-03-25 JP JP2021052453A patent/JP7168173B2/ja active Active
- 2021-06-23 CL CL2021001686A patent/CL2021001686A1/es unknown
- 2021-06-24 CL CL2021001706A patent/CL2021001706A1/es unknown
- 2021-11-03 US US17/518,123 patent/US12351638B2/en active Active
2022
- 2022-06-15 AU AU2022204180A patent/AU2022204180A1/en not_active Abandoned
- 2022-10-18 JP JP2022167222A patent/JP2022183283A/ja active Pending
- 2022-12-27 JP JP2022210140A patent/JP2023024810A/ja active Pending
2024
- 2024-02-02 JP JP2024014929A patent/JP2024032975A/ja not_active Withdrawn
- 2024-08-28 US US18/818,153 patent/US20240409654A1/en active Pending
- 2024-12-05 NL NL301301C patent/NL301301I2/nl unknown
- 2024-12-09 LT LTPA2024535C patent/LTPA2024535I1/lt unknown
- 2024-12-10 FR FR24C1050C patent/FR24C1050I2/fr active Active
- 2024-12-10 NO NO2024054C patent/NO2024054I1/no unknown
- 2024-12-11 HU HUS2400044C patent/HUS2400044I1/hu unknown
- 2024-12-11 FI FIC20240042C patent/FIC20240042I1/fi unknown
- 2024-12-16 JP JP2024220106A patent/JP2025028239A/ja active Pending
2025
- 2025-08-12 JP JP2025134318A patent/JP2025159117A/ja active Pending
- 2025-11-27 AU AU2025271439A patent/AU2025271439A1/en active Pending

Also Published As

Publication number	Publication date
EP4063397A1 (en)	2022-09-28
ZA201800703B (en)	2018-12-19
MY199874A (en)	2023-11-27
HRP20241057T1 (hr)	2024-11-08
CN105384825B (zh)	2018-06-01
SMT202400311T1 (it)	2024-11-15
AU2022204180A1 (en)	2022-07-07
CO2019000946A2 (es)	2019-02-08
US11186647B2 (en)	2021-11-30
AU2016305075A1 (en)	2018-03-08
MY188362A (en)	2021-12-03
JP2022183283A (ja)	2022-12-08
JP2024032975A (ja)	2024-03-12
US20180230225A1 (en)	2018-08-16
EP4063397B1 (en)	2024-06-19
MX2019001294A (es)	2019-04-25
JP2023024810A (ja)	2023-02-16
US20240409654A1 (en)	2024-12-12
KR102512934B1 (ko)	2023-03-23
IL257297A (en)	2018-03-29
AU2021200453A1 (en)	2021-02-25
CN113234174B (zh)	2024-01-09
US12351638B2 (en)	2025-07-08
SG11201900635QA (en)	2019-02-27
PT3896091T (pt)	2023-11-29
PL3896091T3 (pl)	2024-04-29
JP2021087455A (ja)	2021-06-10
US20210163615A1 (en)	2021-06-03
BR112018002844A2 (pt)	2019-04-30
MY192392A (en)	2022-08-18
CR20210225A (es)	2021-06-24
CR20180153A (es)	2018-08-09
FR24C1050I2 (fr)	2025-12-05
MX420844B (es)	2025-02-10
HRP20231542T1 (hr)	2024-03-15
JP2018525033A (ja)	2018-09-06
CA2994579C (en)	2023-07-11
CA3189388A1 (en)	2018-02-15
US20220127371A1 (en)	2022-04-28
CO2018001405A2 (es)	2018-11-22
CL2021001686A1 (es)	2022-01-28
CN113234174A (zh)	2021-08-10
US10934363B2 (en)	2021-03-02
US11535677B2 (en)	2022-12-27
AU2017311089A1 (en)	2019-02-21
CA3019453A1 (en)	2018-02-15
IL257297B (en)	2022-08-01
JP7696731B2 (ja)	2025-06-23
EP3475307A4 (en)	2020-08-19
CL2021001706A1 (es)	2022-01-28
BR112019002687A2 (pt)	2019-05-14
SA519401072B1 (ar)	2024-02-01
AU2016305075B2 (en)	2019-10-10
KR20230052294A (ko)	2023-04-19
JP6859347B2 (ja)	2021-04-14
NO2024054I1 (no)	2024-12-10
EP4424376A3 (en)	2024-12-04
KR20190065999A (ko)	2019-06-12
RS65866B1 (sr)	2024-09-30
JP6851461B2 (ja)	2021-03-31
EA201890302A1 (ru)	2018-10-31
HUS2400044I1 (hu)	2025-01-28
CN113234173A (zh)	2021-08-10
EP4282877A2 (en)	2023-11-29
CN113185615A (zh)	2021-07-30
UA125818C2 (uk)	2022-06-15
PT4063397T (pt)	2024-07-29
ES2966992T3 (es)	2024-04-25
IL294683A (en)	2022-09-01
EP4282878A3 (en)	2024-03-06
LT3896091T (lt)	2023-12-27
MX2018001739A (es)	2018-08-15
SMT202300425T1 (it)	2024-01-10
JP2025028239A (ja)	2025-02-28
DK4063397T3 (da)	2024-07-22
JP2021094037A (ja)	2021-06-24
IL264607A (en)	2019-02-28
EP3334765A1 (en)	2018-06-20
JP2025159117A (ja)	2025-10-17
CN118085090A (zh)	2024-05-28
FR24C1050I1 (fr)	2025-01-17
FI3896091T3 (fi)	2023-12-04
NZ791176A (en)	2025-09-26
KR20240014108A (ko)	2024-01-31
EP3334765A4 (en)	2019-05-08
SI3896091T1 (sl)	2024-03-29
UA126441C2 (uk)	2022-10-05
WO2017025038A1 (en)	2017-02-16
SA518390904B1 (ar)	2023-02-22
ZA201807836B (en)	2019-08-28
KR20240173368A (ko)	2024-12-11
KR20180035918A (ko)	2018-04-06
CN109311999A (zh)	2019-02-05
JP2019527557A (ja)	2019-10-03
CR20190050A (es)	2019-06-11
CN109153731A (zh)	2019-01-04
AU2020200151A1 (en)	2020-01-30
NZ778787A (en)	2025-05-02
RS64925B1 (sr)	2023-12-29
AU2020200151B2 (en)	2022-03-17
KR20250107971A (ko)	2025-07-14
CN113185616B (zh)	2024-03-01
PH12019500193A1 (en)	2019-07-29
ES2984851T3 (es)	2024-10-31
HUE067869T2 (hu)	2024-11-28
AU2025271439A1 (en)	2026-01-08
CL2019000326A1 (es)	2019-10-04
CN113234173B (zh)	2022-03-11
EP3896091B1 (en)	2023-09-27
EP4282878A2 (en)	2023-11-29
CN117756941A (zh)	2024-03-26
FI4063397T3 (fi)	2024-08-09
KR20240017408A (ko)	2024-02-07
MX2024010240A (es)	2024-09-11
EP4282877A3 (en)	2024-02-21
US20210261675A1 (en)	2021-08-26
SG10201913485QA (en)	2020-02-27
FIC20240042I1 (fi)	2024-12-11
MX2022015823A (es)	2023-01-24
AU2017311089B2 (en)	2020-11-19
EP3475307A1 (en)	2019-05-01
CN105384825A (zh)	2016-03-09
PH12018500295B1 (en)	2023-08-11
AU2021200453C1 (en)	2023-11-16
US20200078399A1 (en)	2020-03-12
JP7168173B2 (ja)	2022-11-09
WO2018028647A1 (en)	2018-02-15
DK3896091T5 (da)	2024-08-05
LT4063397T (lt)	2024-09-25
PH12018500295A1 (en)	2021-05-10
LTPA2024535I1 (nl)	2024-12-27
PL4063397T3 (pl)	2024-11-18
CR20210042A (es)	2021-02-26
CN113185616A (zh)	2021-07-30
EA201990208A1 (ru)	2019-07-31
AU2021200453B2 (en)	2023-03-30
NZ750366A (en)	2022-10-28
AU2020200151C1 (en)	2022-09-08
EP3896091A1 (en)	2021-10-20
EP4424376A2 (en)	2024-09-04
MX2024010239A (es)	2024-09-06
CA2994579A1 (en)	2017-02-16
CA3019453C (en)	2023-04-04
HUE064534T2 (hu)	2024-03-28
DK3896091T3 (da)	2023-12-11
SI4063397T1 (sl)	2024-10-30
CN109153731B (zh)	2021-04-02
CL2018000378A1 (es)	2018-08-17

Publication	Publication Date	Title
DK3283625T3 (da)	2020-03-02	Nukleasemedieret genomeditering
DK3331869T3 (da)	2021-02-15	Muscarinagonister
DK3331528T3 (da)	2021-10-25	Muskarinagonister
DK3277719T3 (da)	2022-05-02	Polypeptider
EP3316375A4 (en)	2019-03-06	Redox flow cell
DK3305788T3 (da)	2020-09-28	Janus-kinase-hæmmer
DK3360890T3 (da)	2020-11-02	Genterapi
DK3331529T3 (da)	2021-10-18	Muskarinagonister
DK3310450T3 (da)	2019-08-05	Olie-vand-separator
EP3290364A4 (en)	2019-01-16	Conveyor belt wear monitoring system
DK3270930T3 (da)	2021-10-04	Præeklampsi
EP3381654A4 (en)	2019-06-12	Liquid blow molding method
EP3393959A4 (en)	2020-01-08	GRAB
DK3394281T3 (da)	2020-11-09	Gærcelle
EP3363322A4 (en)	2019-06-19	Hair extender
DK3292136T3 (da)	2021-03-22	Penicillin-g-acylaser
DE112015006486A5 (de)	2018-01-04	Inkubationsrinne
EP3390373C0 (en)	2023-12-13	DOTA SUMMARY
EP3548009A4 (en)	2020-03-18	POLYMERIC NANOPARTICLES
DK3274482T3 (da)	2020-01-06	Stenborsknop
EP3377179A4 (en)	2019-06-05	DEUTERED EPI-743
DE102015206660A8 (de)	2016-12-08	Plattenaufteilanlage
DK3318308T3 (da)	2021-12-20	Badmintonketsjer
DE112015005905A5 (de)	2017-11-02	Gurtschlossbringer
DE112016005599A5 (de)	2018-10-25	Strahlungsgrill